

# (19) United States

# (12) Patent Application Publication (10) Pub. No.: US 2024/0052386 A1 SUN et al.

Feb. 15, 2024 (43) **Pub. Date:** 

### (54) PROTEIN HAVING L-PROLINE EFFLUX FUNCTION, AND USE THEREOF

(71) Applicant: TIANJIN INSTITUTE OF INDUSTRIAL BIOTECHNOLOGY, CHINESE ACADEMY OF SCIENCES, Tianjin (CN)

(72) Inventors: Jibin SUN, Tianjin (CN); Jiao LIU, Tianjin (CN); Ping ZHENG, Tianjin (CN); Moshi LIU, Tianjin (CN); Yu WANG, Tianjin (CN); Wenjuan ZHOU, Tianjin (CN); Guannan SUN, Tianjin (CN)

(21) Appl. No.: 18/260,861

(22) PCT Filed: Jan. 11, 2022

PCT/CN2022/071346 (86) PCT No.:

§ 371 (c)(1),

Jul. 10, 2023 (2) Date:

#### (30)Foreign Application Priority Data

Jan. 13, 2021 (CN) ...... 202110045175.4

### **Publication Classification**

(51)	Int. Cl.	
	C12P 13/24	(2006.01)
	C07K 14/34	(2006.01)
	C12N 1/20	(2006.01)
	C12N 9/12	(2006.01)
	C12N 9/02	(2006.01)


(52) U.S. Cl. CPC ...... C12P 13/24 (2013.01); C07K 14/34 (2013.01); C12N 1/205 (2021.05); C12N 9/1217 (2013.01); C12Y 207/02011 (2013.01); C12N 9/0071 (2013.01); C12Y 114/11002 (2013.01); C12R 2001/15 (2021.05)

#### (57)ABSTRACT

A protein having an L-proline efflux function and the use thereof are provided. A method for producing L-proline or hydroxyproline by means of using a protein ThrE is used for producing L-proline by means of enhancing the activity of a polypeptide, having an L-proline efflux function, in an L-proline-producing strain. Alternatively, the method is used for producing hydroxyproline by means of weakening the activity of a polypeptide, having an L-proline efflux function, in L-proline-producing host cells and enhancing the activity of a proline hydroxylase.

### Specification includes a Sequence Listing.

Created with SnapGene<sup>TM</sup>






FIG. 1




FIG. 2




FIG. 3

# PROTEIN HAVING L-PROLINE EFFLUX FUNCTION, AND USE THEREOF

[0001] The present application claims priority to Chinese Patent Application No. 2021100451754 filed with

[0002] China National Intellectual Property Administration on Jan. 13, 2021, entitled "PROTEIN HAVING L-PROLINE EFFLUX FUNCTION, AND USE THEREOF", which is incorporated herein by reference in its entirety.

### TECHNICAL FIELD

[0003] The present disclosure belongs to the field of molecular biology and bioengineering, and particularly relates to novel use of ThrE, a threonine efflux protein of *Corynebacterium glutamicum*, as an L-proline efflux protein, and a method for producing L-proline and a derivative thereof by using the protein ThrE.

### BACKGROUND

[0004] L-proline is a naturally occurring non-essential amino acid in the human body and has a wide range of applications in the fields of clinics, biomaterials, industry, and the like. Methods for producing L-proline mainly include chemical methods and fermentation methods. The chemical extraction method has gradually lost its marketability due to the serious pollution and high cost, while the microbial fermentation method has become the most widely used method in the modern industry due to its advantages of low production cost, high productivity, high specificity, low environmental pollution, and the like. Currently, the commonly used industrial fermentation strains are Bacillus and Escherichia, commonly used Escherichia such as Escherichia coli, commonly used Bacillus such as Corynebacterium glutamicum, short bacillus such as Brevibacterium flavum, Brevibacterium lactofermentus, as well as some species of the genus Arthrobacter and some species of the genus Microbacterium. Among them, Corynebacterium glutamicum has physiological superiority and thus has become the most important strain used in industry for producing amino acids and other products. In Corynebacterium, L-proline is produced mainly by glutamic acid as a substrate catalyzed by γ-glutamyl kinase (glutamate-5-kinase, ProB), glutamate-semialdehyde dehydrogenase (ProA), and pyrroline-5carboxylate reductase (ProC). In the prior art, L-proline is mainly produced by genetic modifications of ProA and ProB, the key enzymes in a synthetic pathway of L-proline. For example, a mutation at position 149 in the ProB protein derived from Corynebacterium glutamicum can relieve the feedback inhibition of L-proline and increase the yield of L-proline in engineered strains, as reported in CN101084312A. In the fermentation process, the timely transport of an amino acid synthesized in a microorganism to the outside of a cell through a transport pathway is also very important for promoting the biosynthesis of the amino acid. For example, in the production of lysine, the yield of lysine in an engineered strain can be remarkably increased by overexpression of a lysine efflux protein LysE (CN1283797C). However, the use of L-proline efflux protein to increase the yield of L-proline in the production of L-proline has not been reported. Therefore, there is an urgent need in the field to discover an effective L-proline efflux protein, so as to efficiently excrete L-proline produced in a cell to the outside of the cell and obtain a high-yield L-proline-producing engineered bacterium.

### SUMMARY

[0005] In order to overcome the problems in the prior art, in the present disclosure, L-proline efflux proteins of Corynebacterium glutamicum were screened by a whole genome-scale membrane transporter inhibition library. Based on the screening in the present disclosure, it was found that the inhibition of thrE (Cg12622, which has been confirmed in the literature as the gene encoding the threonine efflux protein) gene resulted in a significant decrease in the specific productivity of L-proline. Overexpression of ThrE in a bacterium for producing L-proline, SZCgP1 (Corynebacterium glutamicum ATCC13869, in which a G149D mutation of ProB protein was introduced, with a codon mutation from GGT to GAT, see CN101084312A for details), resulting in a significantly higher extracellular proline concentration throughout the fermentation process and a significantly lower intracellular proline concentration throughout the fermentation process (especially during the rapid acidogenic phase), as compared to a control strain SZCgP1(pEC-control). The above results indicate that ThrE is an L-proline efflux protein.

[0006] An objective of the present disclosure is to provide the use of the proline efflux protein in producing L-proline or hydroxyproline.

[0007] Another objective of the present disclosure is to provide a strain producing L-proline or hydroxyproline.

[0008] Still, another objective of the present disclosure is to provide a method for producing L-proline or hydroxyproline.

[0009] Still, yet another objective of the present disclosure is to provide a method for constructing a strain producing L-proline or hydroxyproline.

[0010] In a first aspect of the present disclosure, provided is use of a polypeptide as a proline efflux protein in producing L-proline and hydroxyproline, the polypeptide being:

[0011] A) a polypeptide having an amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2; or

[0012] B) a polypeptide having some amino acids added or deleted at either or both ends of the polypeptide of A) but still having the activity of an L-proline efflux function; or

[0013] C) a polypeptide having higher than 90%, 95%, 96%, 97%, 98%, or 99% homology to the polypeptide of A) and derived from *Corynebacterium* with the activity of an L-proline efflux function.

[0014] In another preferred embodiment, the polypeptide is a polypeptide derived from a polypeptide having an amino acid sequence set forth in SEQ ID NO: 1 or 2, is formed by adding one or several, preferably 1-20, more preferably 1-15, more preferably 1-10, more preferably 1-3, and most preferably 1 amino acid residue at either or both ends of the amino acid sequence set forth in SEQ ID NO: 1 or 2, and has an L-proline efflux function.

[0015] In another preferred embodiment, the polypeptide has an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2.

[0016] In a second aspect of the present disclosure, provided is a strain for producing L-proline, wherein the strain expresses the following polypeptide:

[0017] A) a polypeptide having an amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2; or

[0018] B) a polypeptide having some amino acids added or deleted at either or both ends of the polypeptide of A) but still having the activity of an L-proline efflux function: or

[0019] C) a polypeptide having higher than 90%, 95%, 96%, 97%, 98%, or 99% homology to the polypeptide of A) and derived from *Corynebacterium* with the activity of an L-proline efflux function.

[0020] In another preferred embodiment, the polypeptide is a polypeptide derived from a polypeptide having an amino acid sequence set forth in SEQ ID NO: 1 or 2, is formed by adding one or several, preferably 1-20, more preferably 1-15, more preferably 1-10, more preferably 1-3, and most preferably 1 amino acid residue at either or both ends of the amino acid sequence set forth in SEQ ID NO: 1 or 2, and has an L-proline efflux function.

[0021] In another preferred embodiment, the polypeptide has an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2.

[0022] In another preferred embodiment, the strain is a bacterium.

[0023] In another preferred embodiment, the strain is selected from *Escherichia* and *Corynebacterium*, preferably *Escherichia coli* and *Corynebacterium glutamicum*, more preferably *Corynebacterium glutamicum*, and more particularly *Corynebacterium glutamicum* ATCC 13032, *Corynebacterium glutamicum* ATCC13869, *Corynebacterium glutamicum* B253, and *Corynebacterium glutamicum* ATCC 14067.

[0024] In another preferred embodiment, glutamate kinase in the bacterium is not subjected to feedback inhibition by L-proline or is subjected to attenuated feedback inhibition by L-proline.

[0025] In another preferred embodiment, the activity of glutamate kinase and/or glutamate-semialdehyde dehydrogenase and/or pyrroline-5-carboxylate reductase in the bacterium is enhanced.

[0026] In a third aspect of the present disclosure, provided is a method for producing L-proline, the method comprising: culturing the strain described above to produce L-proline.

[0027] In another preferred embodiment, the method further comprises a step of isolating L-proline from a fermentation broth.

[0028] In a fourth aspect of the present disclosure, provided is a method for constructing a strain for producing L-proline, the method comprising enhancing the activity of the following polypeptide having an L-proline efflux function in the strain:

[0029] A) a polypeptide having an amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2; or

[0030] B) a polypeptide having some amino acids added or deleted at either or both ends of the polypeptide of A) but still having the activity of an L-proline efflux function: or

[0031] C) a polypeptide having higher than 90%, 95%, 96%, 97%, 98%, or 99% homology to the polypeptide of A) and derived from Corynebacterium with the activity of an L-proline efflux function.

[0032] In another preferred embodiment, the polypeptide is a polypeptide derived from a polypeptide having an amino acid sequence set forth in SEQ ID NO: 1 or 2, is formed by adding one or several, preferably 1-20, more preferably 1-15, more preferably 1-10, more preferably 1-3, and most

preferably 1 amino acid residue at either or both ends of the amino acid sequence set forth in SEQ ID NO: 1 or 2, and has an L-proline efflux function.

[0033] In another preferred embodiment, the polypeptide has an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2.

[0034] In another preferred embodiment, the strain is a bacterium.

[0035] In another preferred embodiment, the strain is selected from *Escherichia* and *Corynebacterium*, preferably *Escherichia coli* and *Corynebacterium glutamicum*, more preferably *Corynebacterium glutamicum*, and more particularly *Corynebacterium glutamicum* ATCC 13032, *Corynebacterium glutamicum* ATCC13869, *Corynebacterium glutamicum* B253, and *Corynebacterium glutamicum* ATCC 14067

[0036] In another preferred embodiment, glutamate kinase in the bacterium is not subjected to feedback inhibition by L-proline or is subjected to attenuated feedback inhibition by L-proline.

[0037] In another preferred embodiment, the activity of glutamate kinase and/or glutamate-semialdehyde dehydrogenase and/or pyrroline-5-carboxylate reductase in the bacterium is enhanced.

[0038] In a fifth aspect of the present disclosure, provided is a host cell in which the activity of a polypeptide having an L-proline efflux function is attenuated, wherein the polypeptide having the activity of the L-proline efflux function is:

[0039] A) a polypeptide having an amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2; or

[0040] B) a polypeptide having some amino acids added or deleted at either or both ends of the polypeptide of A) but still having the activity of the L-proline efflux function: or

[0041] C) a polypeptide having higher than 90%, 95%, 96%, 97%, 98%, or 99% homology to the polypeptide of A) and derived from Corynebacterium with the activity of an L-proline efflux function.

[0042] In another preferred embodiment, the host cell is selected from *Escherichia* and *Corynebacterium*, preferably *Escherichia coli* and *Corynebacterium glutamicum*, more preferably *Corynebacterium glutamicum*, and more particularly *Corynebacterium glutamicum* ATCC 13032, *Corynebacterium glutamicum* ATCC 13869, *Corynebacterium glutamicum* B253, and *Corynebacterium glutamicum* ATCC 14067

[0043] In another preferred embodiment, glutamate kinase in the host cell is not subjected to feedback inhibition by L-proline or is subjected to attenuated feedback inhibition by L-proline.

[0044] In another preferred embodiment, the activity of a proline hydroxylase in the host cell is enhanced.

[0045] In another preferred embodiment, the proline hydroxylase is trans-proline-4-hydroxylase having a nucleotide sequence as set forth in SEO ID NO: 5.

[0046] In another preferred embodiment, the activity of glutamate kinase and/or glutamate-semialdehyde dehydrogenase and/or pyrroline-5-carboxylate reductase in the bacterium is enhanced.

[0047] In a sixth aspect of the present disclosure, provided is a method for producing hydroxyproline such as trans-4-hydroxy-L-proline and the like, the method comprising:

culturing the host cell described above to produce hydroxy-proline such as trans-4-hydroxy-L-proline and the like.

[0048] In another preferred embodiment, the method further comprises a step of isolating hydroxyproline such as trans-4-hydroxy-L-proline and the like from a fermentation broth

[0049] In a seventh aspect of the present disclosure, provided is a method for constructing a strain for producing hydroxyproline such as trans-4-hydroxy-L-proline and the like, wherein the method comprises:

[0050] (1) attenuating the activity of the following polypeptide having an L-proline efflux function in the strain, wherein the polypeptide having the activity of the L-proline efflux function is:

[0051] A) a polypeptide having an amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2; or

[0052] B) a polypeptide having some amino acids added or deleted at either or both ends of the polypeptide of A) but still having the activity of the L-proline efflux function; or

[0053] C) a polypeptide with homology higher than 90%, 95%, 96%, 97%, 98%, or 99% with the polypeptide of A) and derived from Corynebacterium with the activity of an L-proline efflux function;

[0054] (2) relieving or attenuating feedback inhibition by L-proline on glutamate kinase; and

[0055] (3) introducing a gene encoding a proline hydroxylase into the strain obtained in step (2).

[0056] In another preferred embodiment, the activity of glutamate kinase and/or glutamate-semialdehyde dehydrogenase and/or pyrroline-5-carboxylate reductase in the bacterium is enhanced.

[0057] In another preferred embodiment, the proline hydroxylase is trans-proline-4-hydroxylase having a nucleotide sequence as set forth in SEQ ID NO: 5.

[0058] The beneficial effects of the present disclosure are as follows:

[0059] 1. In the present disclosure, after screening, ThrE, a threonine efflux protein, is found to be an L-proline efflux protein of *Corynebacterium glutamicum*. Production bacteria for L-proline, SZCgP1 and SZCgP3, are constructed based on strains ATCC13869 and ATCC13032 of *Corynebacterium glutamicum*, and overexpression of ThrE in the two strains can increase the yield of L-proline by 1.57 times and 2.56 times, respectively. Therefore, the present disclosure can be used in practice for producing L-proline by bacterial fermentation, is convenient to popularize and apply, and has considerable industrial application value.

[0060] 2. In the present disclosure, ThrE is also used in the production of hydroxyproline such as trans-4-hydroxy-L-proline and the like, and knockout of thrE gene remarkably reduces the yield of extracellular L-proline by-products and increases the ratio of hydroxyproline such as trans-4-hydroxy-L-proline and the like to L-proline, helping to obtain hydroxyproline such as trans-4-hydroxy-L-proline and the like with higher purity. The knockout of thrE gene is of great significance to the production of hydroxyproline products such as trans-4-hydroxy-L-proline and the like.

[0061] 3. The present disclosure provides a novel approach for constructing a hydroxyproline-producing strain by knocking out the L-proline efflux protein in the strain. This allows for an increase in the intracel-

lular concentration of L-proline, which serves as a substrate for hydroxylation by proline hydroxylase. As a result, the intracellular L-proline is converted into hydroxyproline, thereby offering valuable insights for the development of higher-yielding hydroxyproline-producing strains in the field of biotechnology.

### BRIEF DESCRIPTION OF THE DRAWINGS

[0062] FIG. 1 shows a plasmid map of pCas9gRNA-ccdB; [0063] FIG. 2 shows a plasmid map of pEC-thrE1; and [0064] FIG. 3 shows a plasmid map of pEC-thrE2.

### DETAILED DESCRIPTION

[0065] The technical solutions of the present disclosure will be further illustrated in detail with reference to the following specific examples. It will be appreciated that the following examples are merely exemplary illustrations and explanations of the present disclosure, and should not be construed as limiting the protection scope of the present disclosure. All techniques implemented based on the content of the present disclosure described above are included within the protection scope of the present disclosure.

[0066] Unless otherwise stated, the starting materials and reagents used in the following examples are all commercially available products or can be prepared using known methods. Where specific conditions are not indicated in experimental methods in the following examples, conventional conditions such as those described in Sambrook et al., *Molecular Cloning: A Laboratory Manual* (New York: Cold Spring Harbor Laboratory Press, 1989) or conditions recommended by the manufacturer are followed.

### Definitions and Description:

[0067] The term "polypeptide having an L-proline efflux function" used herein refers to a protein or a polypeptide that can excrete L-proline in a cell to the outside of the cell, which may be a protein set forth in SEQ ID NO: 1 or SEQ ID NO: 2, or a protein or a polypeptide that is obtained by mutating SEQ ID NO: 1 or SEQ ID NO: 2 and still has an L-proline efflux function.

[0068] The terms "protein", "polypeptide" and "peptide" used herein are used interchangeably, have the meanings commonly understood by one of ordinary skill in the art, and refer to amino acid polymers of any length. The polymers may be linear or branched. They may comprise modified amino acids and may be interrupted by non-amino acids. The terms also encompass amino acid polymers that have been modified (e.g., disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other operation, such as conjugation with a labeling component).

[0069] The term "fusion protein" used herein refers to a protein obtained by fusing the mutant protein with a protein tag. The protein tag can be located at the N-terminus of the mutant protein or at the C-terminus of the mutant protein. The mutant protein and the protein tag may also have a spacer amino acid residue therebetween, and specifically may have fewer than 10 spacer amino acid residues therebetween.

[0070] The term "host cell" herein means any type of cell that is susceptible to transformation, transfection, transduction, and the like using the polypeptide having the activity of the L-proline efflux function of the present disclosure, a polynucleotide encoding the polypeptide, or an expression

vector. The term "recombinant microorganism" encompasses host cells which differ from parent cells after introduction of a transcription initiation element or a recombinant expression vector, specifically, the recombinant host cells are achieved by transformation. For example, suitable host cells for use in the present disclosure include, but are not limited to, Escherichia and Corynebacterium, preferably Escherichia coli and Corynebacterium glutamicum, more preferably Corynebacterium glutamicum, and more particularly Corynebacterium glutamicum ATCC 13032, Corynebacterium glutamicum ATCC 13032, Corynebacterium glutamicum B253, and Corynebacterium glutamicum ATCC 14067.

[0071] The term "transformation" herein has the meaning generally understood by those skilled in the art, i.e., the process of introducing exogenous DNA into a host. Methods for the transformation include any method for introducing a nucleic acid into a cell, including, but not limited to, electroporation, calcium phosphate precipitation, calcium chloride (CaCl<sub>2</sub>) precipitation, microinjection, polyethylene glycol (PEG) method, DEAE-dextran method, cationic liposome method, and lithium acetate-DMSO method.

[0072] The culture of the host cell herein may be performed according to a conventional method in the art, including, but not limited to, well plate culture, shake-flask culture, batch culture, continuous culture, fed-batch culture, and the like, and various culture conditions such as temperature, time, pH of a medium, and the like may be appropriately adjusted according to actual circumstances.

[0073] The terms "comprise", "have", "include", or "contain" used herein are intended to be inclusive or open-ended and do not exclude additional, unspecified elements or method steps.

[0074] The term "about" used herein means that a value includes the standard deviation of error for the device or method used to determine the value.

[0075] The term "or" used herein is defined as merely an alternative and "and/or", but unless it is explicitly stated to be only an alternative or mutually exclusive between alternatives, the term "or" in the claims means "and/or".

[0076] The selected/optional/preferred "numerical range" used herein includes both numerical endpoints at both ends of the range and all natural numbers covered between the numerical endpoints with respect to the aforementioned numerical endpoints.

[0077] The terms "wild-type" and "naturally occurring" used herein refer to an object that can be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism, that can be isolated from a source in nature, and that has not been intentionally modified by humans in the laboratory, is naturally occurring.

[0078] The term "amino acid mutation" or "nucleotide mutation" used herein includes "substitution, repetition, deletion, or addition of one or more amino acids or nucleotides". In the present disclosure, the term "mutation" refers to an alteration in nucleotide sequence or amino acid sequence. In a specific embodiment, the term "mutation" refers to "substitution".

[0079] The term "native state" used herein refers to the activity of a polypeptide in a microorganism in an unmodified state, i.e., the activity in the native state.

[0080] The term "having the activity of an L-proline efflux function" used herein has the same or similar meaning as conventionally understood by those skilled in the art. It

means that the amino acid sequence of a fragment is a portion of the amino acid sequence of an intact protein or polypeptide, and has the same or similar function or activity as the intact protein or polypeptide. Specifically, in the present disclosure, it indicates any amino acid fragment obtained from the ThrE protein of the present disclosure and having an L-proline efflux function.

[0081] It is known to those skilled in the art that, for mutating a wild-type polypeptide in order to improve the activity, it is more important to find a site that can achieve the desired purpose. Therefore, based on the teachings of the present disclosure, a person skilled in the art will mutate the amino acid sequence set forth in SEQ ID NO: 1 or 2 and test the mutant for the relevant activity. In addition, it is not difficult for one of ordinary skill in the art to know that altering a few amino acid residues in certain regions of a polypeptide, e.g., in non-critical regions, does not substantially alter biological activity. For example, the sequence obtained by properly replacing some amino acids does not affect its activity (see Watson et al., Molecular Biology of The Gene, fourth edition, 1987, The Benjamin/Cummings Pub. Co. P224). Therefore, one of ordinary skill in the art would be able to implement such replacements and ensure that the resulting molecule retains the desired biological activity.

[0082] Therefore, it is apparent that further mutations of the L-proline efflux protein of the present disclosure result in further mutants that still have corresponding functions and activities. For example, it is well known to those skilled in the art that adding or removing several amino acid residues, e.g., preferably 1-20, more preferably 1-15, more preferably 1-10, more preferably 1-3, and most preferably 1 amino acid residue, to or from either end of a polypeptide does not affect the function of the resulting mutant. For example, for ease of purification, a skilled person usually makes the resulting protein have a 6×His tag at either end, and such protein has the same function as a protein that does not have the 6×His tag. Therefore, the present disclosure shall include conservative mutations obtained based on the present disclosure.

[0083] The term "conservative mutation" refers to a mutation that can normally maintain the function of a protein. A representative example of the conservative mutation is a conservative replacement.

[0084] As used in the present disclosure, the term "conservative replacement" relates to the replacement of an amino acid residue with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art and include those having basic side chains (e.g., lysine, arginine, and histidine), acidic side chains (e.g., aspartic acid and glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, and cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, and tryptophan), (3-branched chains (e.g., threonine, valine, and isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, and histidine).

[0085] As used in the present disclosure, the "conservative replacement" typically refers to the substitution of one type of amino acid at one or more sites in a protein. Such substitution may be conservative. Examples of replacements regarded as conservative replacements include replacement of Ala with Ser or Thr, replacement of Arg with Gln, His or Lys, replacement of Asn with Glu, Gln, Lys, His or Asp,

replacement of Asp with Asn, Glu or Gln, replacement of Cys with Ser or Ala, replacement of Gln with Asn, Glu, Lys, His, Asp or Arg, replacement of Glu with Gly, Asn, Gln, Lvs or Asp, replacement of Gly with Pro, replacement of His with Asn, Lys, Gln, Arg or Tyr, replacement of Ile with Leu, Met, Val or Phe, replacement of Leu with Ile, Met, Val or Phe, replacement of Lys with Asn, Glu, Gln, His or Arg, replacement of Met with Ile, Leu, Val or Phe, replacement of Phe with Trp, Tyr, Met, Ile, or Leu, replacement of Ser with Thr or Ala, replacement of Thr with Ser or Ala, replacement of Trp with Phe or Tyr, replacement of Tyr with His, Phe or Trp, and replacement of Val with Met, Ile or Leu. In addition, the conservative mutations also include naturally occurring mutations caused by individual differences, differences in strain and species, and the like from which genes are derived.

[0086] The term "corresponding to" used herein has the meaning commonly understood by one of ordinary skill in the art. Specifically, the term "corresponding to" refers to a position in a sequence corresponding to a specified position in another sequence after alignment of the two sequences by homology or sequence identity. Thus, for example, in terms of "an amino acid residue corresponding to position 40 of the amino acid sequence set forth in SEQ ID NO: 1", if a 6×His tag is added to one end of the amino acid sequence set forth in SEQ ID NO: 1, then position 40 of the resulting mutant corresponding to the amino acid sequence set forth in SEQ ID NO: 1 may be position 46.

[0087] In a specific embodiment, the homology or sequence identity may be no less than 90%, preferably no less than 95%, and more preferably 96%, 97%, 98%, or 99% homology.

[0088] Methods for determining sequence homology or identity well known to one of ordinary skill in the art include, but are not limited to: Computational Molecular Biology, Ed. Lesk, A. M., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Ed. Smith, D. W., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part One, Ed. Griffin, A. M. and Griffin, H. G., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Sequence Analysis Primer, Ed. Gribskov, M. and Devereux, J., M Stockton Press, New York, 1991; and Carillo, H. and Lipman, D., SIAM J. Applied Math., 48:1073 (1988). A preferred method for determining identity is to obtain the greatest match between the sequences tested. Methods for determining identity are compiled in publicly available computer programs. Preferred computer program methods for determining identity between two sequences include, but are not limited to: GCG program package (Devereux, J. et al., 1984), BLASTP, BLASTN, and FASTA (Altschul, S, F. et al., 1990). The BLASTX program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S. et al., NCBI NLM NIH Bethesda, Md.20894; Altschul, S. et al., 1990). The well-known Smith Waterman algorithm can also be used to determine identity.

**[0089]** Unless defined otherwise, or clear from the background, all technical and scientific terms used in the present disclosure have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure belongs.

### EXAMPLE 1

Screening of L-Proline Efflux Proteins of Corynebacterium Glutamicum in Corynebacterium Glutamicum ATCC13869

[0090] The inventors screened L-proline efflux proteins of Corynebacterium glutamicum by a whole genome-scale membrane transporter inhibition library. Firstly, the cas9 gene of the pCas9 plasmid was mutated with D10A and H840A, and the Bsa I restriction enzyme site in the plasmid backbone was removed, resulting in the pdCas9 plasmid (LIU, Jiao, et al. Development of a CRISPR/Cas9 genome editing toolbox for Corynebacterium glutamicum. Microbial cell factories, 2017, 16.1: 205.). Subsequently, a gRNAccdB expression cassette was amplified from a pnCas9 (D10A)-AID-gRNA-ccd $B^{TS}$  plasmid (WANG, Yu, et al. Expanding targeting scope, editing window, and base transition capability of base editing in Corynebacterium glutamicum. Biotechnology and bioengineering, 2019, 116: 3016-3029) and cloned into the same position of pdCas9 to obtain pdCas9gRNA-ccdB as a CRISPRi plasmid that could be efficiently constructed and had a sequence as set forth in SEQ ID NO: 3. The inhibition efficiency of the system could reach 96%. Based on the above ingenious design, for the inhibition of the target gene, only a sgRNA with a 20 bp target DNA binding region was required to be designed, then two complementary primers of 24 bp were synthesized and annealed to form a double-stranded DNA fragment, and an inhibition plasmid of the target gene was constructed by Golden Gate cloning. The inventors also constructed a control plasmid pdCas9gRNA-control without the 20 bp DNA binding region. Whole genome-scale protein sequences of Corynebacterium glutamicum ATCC13869 were used in a TransportDB database for membrane transporter protein prediction to obtain 397 membrane transporters on the whole genome scale. Thereafter, inhibition plasmids of genes of the 397 membrane transporters were constructed based on the CRISPRi system, and the inhibition library plasmids and the control plasmid were separately introduced into a bacterium for producing L-proline, SZCgP1 (Corynebacterium glutamicum ATCC13869, in which a G149D mutation of proB gene was introduced, with a codon mutation from GGT to GAT, see CN101084312A for details), so as to obtain inhibition library strains. Finally, all of the strains were evaluated for the specific productivity of L-proline by fermentation on 96-well plates and genes with decreased specific productivity of L-proline after inhibition were potential L-proline efflux protein genes. Based on the above screening, the inventors found that the inhibition of thrE (Cg12622, which has been confirmed in the literature as an L-threonine efflux protein) gene resulted in a significant decrease in the specific productivity of L-proline. Primers for the construction of the CRISPRi plasmids of the thrE gene were thrE-F and thrE-R (Table 1). The control strain was SZCgP1(pdCas9gRNA-control), the inhibition plasmid of the thrE gene was pdCas9gRNA-thrE, and the inhibition strain of the thrE gene was SZCgP1 (pdCas9gRNA-thrE).

TABLE 1

Primer	Nucleotide sequence	SEQ ID NO.
thrE-F	TTCACACTGCTC GAACTTGTACCT	6
thr E-R	AAACAGGTACAA GTTCGAGCAGTG	7

[0091] To further confirm the effect of the thrE gene inhibition on L-proline production, evaluations were performed by fermentation using a 24-well deep-well plate. The seed culture medium contained the following ingredients (g/L): 5 g/L glucose, 1 g/L yeast powder, 3 g/L soybean peptone, 3 g/L urea, 0.5 g/L succinic acid, 1 g/L K<sub>2</sub>HPO<sub>4</sub>. 3H<sub>2</sub>O, 0.1 g/L MgSO<sub>4</sub>·7H<sub>2</sub>O, 0.01 mg/L biotin, 0.1 mg/L vitamin B1, and 20 g/L MOPS. The fermentation culture medium contained the following ingredients: 80 g/L glucose, 1 g/L yeast powder, 1 g/L soybean peptone, 1 g/L NaCl, 1 g/L ammonium sulfate, 6 g/L urea, 1 g/L g/L MOPS, and the initial pH was 7.2. Firstly, the strains were inoculated into a seed culture medium containing 15 μg/mL chloramphenicol and cultured for 8 h. The cultures were inoculated as seeds into a 24-well plate containing 15 μg/mL chloramphenicol and a 0.03 mM IPTG fermentation culture medium. The volume of the medium was 800 µL, and the inoculation amount was controlled with the initial  $OD_{600}$  being 0.03 (as detected by a microplate reader). The seeds were cultured at 30° C. for 21 h, with the rotation speed of a plate shaker being 800 rpm. The experiment for each strain was performed in triplicate. After fermentation, OD<sub>600</sub> and the yield of L-proline were detected. The detection of L-proline was performed as follows: The fermentation solution was diluted with 3% (W/V) sulfosalicylic acid to a proper concentration. 1 mL of the dilution was taken. and 1 mL of an acid-ninhydrin complex (1.25 g of ninhydrin dissolved in 30 mL of glacial acetic acid and 20 mL of 6M H<sub>3</sub>PO<sub>4</sub> by heating at 70° C.) and 1 mL of glacial acetic acid were added. The mixture was reacted in a boiling water bath at 100° C. for 45 min. After cooling, OD<sub>520</sub> was determined. A standard curve was plotted by adopting L-proline at concentrations of 0-100 mg/L, and the concentrations of the samples to be tested were calculated according to the standard curve. The results are shown in Table 2, indicating that the yield and specific productivity of L-proline of the strains decreased by 63% and 49%, respectively, after the inhibition of thrE gene expression.

TABLE 2

Effect of inhibition of thrE gene expression on yield and specific productivity of L-proline								
Strain	OD <sub>600</sub>	Yield of L-proline (g/L)	Specific productivity of L-proline (g/L/OD <sub>600</sub> )					
SZCgP1(pdCas9gRNA- control)	13.60 ± 1.42	5.05 ± 0.50	0.37 ± 0.00					
SZCgP1(pdCas9gRNA-thrE)	9.91 ± 0.64	1.87 ± 0.29	0.19 ± 0.03					

### EXAMPLE 2

Identification of L-Proline Efflux Proteins of Corynebacterium Glutamicum in Corynebacterium Glutamicum ATCC13869

[0092] (1) Construction of Knockout, Complementation and Overexpression Strains of thrE Gene in SZCgP1 Strains [0093] The inventors constructed knockout mutants based on CRISPR/Cas9 genome editing technology. Using a pCas9 plasmid (LIU, Jiao, et al. Development of a CRISPR/ Cas9 genome editing toolbox for Corynebacterium glutamicum. Microbial cell factories, 2017, 16.1: 205.) as a template and cas9-1/cas9-2 as primers, a lacO mutation (a TGTGTGGAATTGTGAGCGGAmutation from TAACAATTTCACACA TGTGTGGAATTGTto GAGCGCTCACAATTTCACACA) and an RBS mutation AAAGGAGTTGAGA mutation from AAAGGCACCCGAT) as manipulation elements introduced on the primers, and a fragment containing cas9 was amplified. Thereafter, a plasmid backbone fragment containing a gRNA-ccdB expression cassette and a temperature-sensitive replication origin was amplified by using a pnCas9(D10A)-AID-gRNA-ccdB<sup>7S</sup> plasmid (WANG, Yu, et al. Expanding targeting scope, editing window, and base transition capability of base editing in Corynebacterium glutamicum. Biotechnology and bioengineering, 2019, 116: 3016-3029) as a template and gRNA-1/gRNA-2 as primers. The above 2 fragments were cloned and ligated by a one-step recombination kit from Vazyme to obtain a pCas9gRNA-ccdB plasmid that could be efficiently constructed and had a plasmid map as shown in FIG. 1 and a sequence as set forth in SEQ ID NO: 4. According to the reported genome sequence of Corynebacterium glutamicum ATCC13869, upstream and downstream homologous arms were amplified by using ATCC13869 genome as a template with thrE-1/ thrE-2 and thrE-3/ thrE-4 as primers, respectively. 3 plasmid backbone fragments were amplified by using a pCas9gRNA-ccdB plasmid as a template with cas9-3/cas9-4, cas9-5/cas9-6, and gRNA-3/gRNA-4 as primers, respectively, and a gRNA with 20bp target DNA binding region was also introduced. The above 5 fragments were cloned and ligated by a one-step recombination kit from Vazyme to obtain a pCas9gRNA-thrE plasmid. SZCgP1 strain was prepared to be competent, and about 2 µg of the pCas9gRNA-thrE plasmid was electrotransformed. 1 mL of a TSB culture medium pre-heated at 46° C. was added, and the heat shock was performed at 46° C. for 6 min. The mixture was incubated at 30° C. for 3 h, applied onto a TSB plate containing 15 µg/mL chloramphenicol and 0.05 mM IPTG, and cultured for 2 days. A correct mutant verified by PCR and sequencing was named as SZCgP2 strain.

[0094] To construct the overexpression plasmid, the thrE gene was cloned onto the pEC-ccdB plasmid, which is derived from the pEC-XK99E plasmid. The pEC-ccdB plasmid was digested using a Bsa I enzyme. According to the reported genome sequence of Corynebacterium glutamicum ATCC13869, a fragment of thrE1 gene was amplified with thrE-5/thrE-6 by using the genome of ATCC13869 as a template, and an amino acid sequence of a protein encoded by the thrE1 gene is as set forth in SEQ ID NO: 1. The two segments were cloned and ligated by a one-step recombination kit from Vazyme to obtain a pEC-thrE1 plasmid having a plasmid map as shown in FIG. 2. A control plasmid pEC-control, in which no gene was cloned, was also constructed. The pEC-thrE1 plasmid was transformed into the SZCgP2 strain to obtain a complementation strain SZCgP2 (pEC-thrE1). The pEC-thrE1 and pEC-control plasmids were transformed into SZCgP1 to obtain an overexpression strain SZCgP1(pEC-thrE1) and a control strain SZCgP1

(pEC-control), respectively.

TABLE 3

		SEQ ID
Primer	Nucleotide sequence	NO.
cas9-1	GCGCTCACAATTTCACACAGGAAACAG AATTAATTAAGCTTAAAGGCACCCGAT ATGGATAAGAAATACTCAATAGGC	8
cas9-2	TCAGTCACCTCCTAGCTGACTCAAATC	9
gRNA-1	GTCAGCTAGGAGGTGACTGAAGCTTGG CTGTTTTGGCGGATG	10
gRNA-2	CTGTGTGAAATTGTGAGCGCTCACAAT TCC	11
Cas9-3	TCGAAGGGCACCAATAACTGC	12
Cas9-4	CTTTTACTTTCACCAGCGTTTCTG	13
Cas9-5	AACGCTGGTGAAAGTAAAAGATGC	14
Cas9-6	GAATGGAACGGATCAAACGGTGAATTA CACTGTACCTGTTGCGTC	15
gRNA-3	CCGTTTGATCCGTTCCATTCGTTTTAG AGCTAGAAATAGCAAG	16
gRNA-4	CAACCTGCCATCACGAGATTTTC	17
thrE-1	AATCTCGTGATGGCAGGTTGACGGGAG CCTAAGTGAAATG	18
thrE-2	CCTTGGTAAATGCACGGTATGGGTCAG TGAGATCAATCGGG	19
thrE-3	CCATACCGTGCATTTACCAAGG	20
thrE-4	CAGTTATTGGTGCCCTTCGACTTTGTG GTCTTCTTTGCGG	21
thrE-5	ACAGGCCAAAGGAGTTGAGAATGTTGA GTTTTGCGACCC	22
thrE-6	CCAAGCTTGCATGCCTGCAGTTACCTT TTATTACCGAATC	23

(2) Determination of Intracellular and Extracellular L-Proline Concentrations of Knockout, Complementation and Overexpression Strains of thrE Gene by Shake-Flask Fermentation

[0095] To further confirm whether the thrE gene is an L-proline efflux protein, intracellular and extracellular L-proline concentrations of knockout, complementation and overexpression strains were determined using shake-flask fermentation. The seed culture medium contained the following ingredients (g/L): 5 g/L glucose, 1 g/L yeast powder, 3 g/L soybean peptone, 3 g/L urea, 0.5 g/L succinic acid, 1 g/L K<sub>2</sub>HPO<sub>4</sub>·3H<sub>2</sub>O, 0.1 g/L MgSO<sub>4</sub>·7H<sub>2</sub>O, 0.01 mg/L biotin, 0.1 mg/L vitamin B1, and 20 g/L MOPS. The fermentation culture medium contained the following ingredients: 80 g/L glucose, 1 g/L yeast powder, 1 g/L soybean peptone, 1 g/L NaCl, 1 g/L ammonium sulfate, 6 g/L urea, 1 g/L K<sub>2</sub>HPO<sub>4</sub>·3H<sub>2</sub>, 0.45 g/L MgSO<sub>4</sub>·7H<sub>2</sub>O, 0.05 g/L FeSO<sub>4</sub>.7H<sub>2</sub>O, 0.4 mg/L biotin, 0.1 mg/L vitamin B1, and 40 g/L MOPS, and the initial pH was 7.2. Firstly, the strains were inoculated into a seed culture medium and cultured for 8 h. The cultures were inoculated as seeds into 250 mL triangular flasks containing a fermentation culture medium, the volume of the medium being 25 mL. 25 µg/mL kanamycin and 0.05 mM IPTG were added as needed, and the inoculation amount was controlled with the initial o Da) being 0.1 (as determined by a spectrophotometer). The mixture was cultured at 30° C. for 21 h, with the rotation speed of a shaker being 2200 rpm. The experiment for each strain was performed in triplicate. Samples were taken in the fermentation process to determine  $\mathrm{OD}_{600}$ , intracellular L-proline concentration and extracellular L-proline concentration.

[0096] The intracellular and extracellular L-proline concentrations were determined as follows: 400 µL of silicone oil was added into a 1.5 mL centrifuge tube in advance, and 400 μL of the fermented bacterial solution was quickly pipetted and then slowly added into the tube. The mixture was centrifuged at 4° C. and 12000 rpm for 10 min, and the supernatant was obtained as an extracellular sample. The bacteria precipitate at the bottom of the centrifuge tube was cut off and placed in a 1.5 mL centrifuge tube. A proper amount of 3% sulfosalicylic acid was added according to the amount of the bacteria. The mixture was boiled at 100° C. for 20 min and centrifuged at 12000 rpm for 10 min, and the supernatant was obtained as an intracellular sample. The detection of L-proline was performed as described in Example 1, and the intracellular L-proline concentration was calculated based on the volume of Corynebacterium gluta*micum* reported in the literature.

[0097] The results of the determination of the intracellular and extracellular L-proline concentrations of each strain in the fermentation process are as shown in Tables 4 and 5. The extracellular L-proline concentration of the thrE geneknockout strain SZCgP2 was significantly lower than that of the starting strain SZCgP1 throughout the fermentation process, and the intracellular L-proline concentration of the knockout strain was slightly higher than that of the starting strain SZCgP1 in the early stage (3-9 h) of the fermentation. The extracellular L-proline concentration of the complementation strain SZCgP2(pEC-thrE1) was significantly higher than that of the starting strain SZCgP1 throughout the fermentation process, and the intracellular L-proline concentration of the complementation strain was significantly lower than that of the starting strain during the rapid acidogenic phase (3-15 h). The extracellular L-proline concentration of the overexpression strain SZCgP1(pEC-thrE1) was significantly higher than that of the control strain SZCgP1(pEC-control) throughout the fermentation process, and the intracellular L-proline concentration of the overexpression strain was significantly lower than that of the control strain SZCgP1(pEC-control) throughout the fermentation process (especially during the rapid acidogenic phase). Based on the above results, it was indicated that ThrE is a proline efflux protein. The overexpression of ThrE in the SZCgP1 strain could increase the yield of L-proline, and the overexpression strain SZCgP1(pEC-thrE1) showed a 1.57-fold increase in the yield of extracellular L-proline at 21 h relative to the control bacterium SZCgP1(pEĈ-control) introduced with an empty plasmid, indicating that the overexpression of the L-proline efflux protein gene is of great significance in the modification of a strain producing L-pro-

TABLE 4

Intracellular L-proline concentrations of knockout, complementation and overexpression strains of thrE gene in *Corynebacterium glutamicum* ATCC13869

Tetre celled an I must be a second setting (mM)

	Intracentiar L-profine concentration (mivi)										
Time	SZCgP1	SZCgP2	SZCgP2 (pEC- thrE1)	SZCgP1 (pEC- thrE1)	SZCgP1 (pEC- control)						
3 h 6 h	151 ± 17 192 ± 17	213 ± 21 239 ± 13	83 ± 1 72 ± 3	67 ± 10 73 ± 2	123 ± 7 221 ± 61						

TABLE 4-continued

Intracellular L-proline concentrations of knockout, complementation and overexpression strains of thrE gene in *Corynebacterium glutamicum* ATCC13869

#### Intracellular L-proline concentration (mM) SZCgP2 SZCgP1 SZCgP1 (pEC-(pEC-(pEC-SZCgP1 SZCgP2 Time thrE1) thrE1) control) 9 h 296 ± 18 $315 \pm 15$ 116 ± 19 $106 \pm 10$ $246 \pm 37$ 12 h $287 \pm 19$ $256 \pm 14$ $112 \pm 8$ $107 \pm 5$ $228 \pm 21$ 15 h $206 \pm 37$ $235 \pm 15$ $101 \pm 2$ $92 \pm 3$ $228 \pm 11$ 18 h $103 \pm 5$ $110 \pm 6$ $105 \pm 3$ $95 \pm 2$ $159 \pm 9$ $76 \pm 6$ $70 \pm 1$ 111 ± 4 $105 \pm 5$ $108 \pm 9$

L-proline at 21 h relative to the control bacterium SZCgP3 (pEC-control) introduced with an empty plasmid, further indicating that the overexpression of the L-proline efflux protein gene in *Corynebacterium glutamicum* is of great significance in the production of L-proline.

TABLE 6

Yi	Yield of extracellular L-proline of thrE gene overexpression strain in Corynebacterium glutamicum ATCC13032									
		Yield of extracellu	lar L-proline (g/L)							
	Time	SZCgP3(pEC-control)	SZCgP3(pEC-thrE2)							
3	h	0.02 ± 0.00	$0.03 \pm 0.00$							
6	h	$0.05 \pm 0.00$	$0.17 \pm 0.01$							
9	9 h $0.22 \pm 0.02$ $0.80 \pm 0.09$									

TABLE 5

Extracellular L-proline concentrations of knockout, complementation and overexpression strains of thrE gene in *Corynebacterium glutamicum* ATCC13869

	Extracellular L-proline concentration (g/L)									
Time	SZCgP1	SZCgP2	SZCgP2 (pEC- thrE1)	SZCgP1 (pEC- thrE1)	SZCgP1 (pEC- control)					
3 h	0.05 ± 0.00	0.03 ± 0.00	0.08 ± 0.00	0.08 ± 0.00	0.04 ± 0.00					
6 h	$0.15 \pm 0.00$	$0.03 \pm 0.00$	$0.32 \pm 0.03$	$0.30 \pm 0.02$	$0.12 \pm 0.01$					
9 h	$0.65 \pm 0.02$	$0.20 \pm 0.04$	$1.40 \pm 0.10$	$1.98 \pm 0.26$	$0.47 \pm 0.02$					
12 h	$1.49 \pm 0.37$	$0.47 \pm 0.00$	$3.14 \pm 0.35$	$3.09 \pm 0.14$	$0.87 \pm 0.09$					
15 h	$5.41 \pm 0.12$	$2.42 \pm 0.05$	$11.61 \pm 0.96$	$11.77 \pm 1.14$	$4.40 \pm 0.16$					
18 h 21 h	5.41 ± 1.09 5.56 ± 0.41	$3.40 \pm 0.69$ 2 71 ± 0.29	17.01 ± 0.96	16.40 ± 4.23	$5.34 \pm 1.48$ $6.32 \pm 0.31$					
21 11	5.50 2 0.11	2.71 = 0.25	17.07 = 2.50	10.22 - 1.51	0.52 2 0.51					

EXAMPLE 3

# Use of L-Proline Efflux Protein in Production of L-Proline in *Corynebacterium Glutamicum*ATCC13032 Strain

[0098] Firstly, a strain producing L-proline, SZCgP3, was constructed based on a Corynebacterium glutamicum ATCC13032 strain, i.e., a G149K mutation of proB gene was introduced, with a codon mutation from GGT to AAG (see CN101084312A). The construction of a ThrE overexpression strain was similar to that of a Corynebacterium glutamicum 13869 strain. Overexpression of thrE was performed on a pEC-ccdB plasmid, a derivative plasmid of pEC-XK99E plasmid, and the pEC-ccdB plasmid was digested using a Bsa I enzyme. A fragment of thrE2 gene was amplified with thrE-5/thrE-6 by using the genome of Corynebacterium glutamicum ATCC13032 as a template, and an amino acid sequence of a protein encoded by the thrE2 gene is as set forth in SEQ ID NO: 2. The two segments were cloned and ligated by a one-step recombination kit from Vazyme to obtain a pEC-thrE2 plasmid having a plasmid map as shown in FIG. 3. The pEC-thrE2 and pEC-control plasmids were transformed into SZCgP3 to obtain an overexpression strain SZCgP3(pEC-thrE2) and a control strain SZCgP3(pEC-control), respectively. The yield of extracellular L-proline of the above strains was evaluated by shake-flask fermentation, and the fermentation was performed as described in Example 2. The results are shown in Table 6, indicating that the overexpression of ThrE in Corynebacterium glutamicum SZCgP3 could increase the yield of L-proline, and the overexpression strain SZCgP3 (pEC-thrE2) showed a 2.56-fold increase in the yield of

TABLE 6-continued

Yield of extracellular L-proline of thrE gene overexpression strain in Corynebacterium glutamicum ATCC13032

Yield of extracellular L-proline (g/L)

Time	SZCgP3(pEC-control)	SZCgP3(pEC-thrE2)
12 h 15 h 18 h 21 h	$0.59 \pm 0.01$ $1.00 \pm 0.03$ $3.85 \pm 0.36$ $3.81 \pm 0.47$	$1.56 \pm 0.07$ $3.56 \pm 0.22$ $10.55 \pm 0.36$ $13.56 \pm 1.26$

### EXAMPLE 4

Use of L-Proline Efflux Protein in Production of Hydroxyproline

[0099] Firstly, an expression plasmid pEC-mip4h was constructed for expressing trans-proline-4-hydroxylase, based on the pEC-XK99E plasmid, as described in Patent No. CN201710661945.1. The sequence of trans-proline-4-hydroxylase is provided as SEQ ID NO: 5. The pEC-mip4h plasmid and the pEC-XK99E control plasmid were transformed into an SZCgP1 strain to obtain an overexpression strain SZCgP1(pEC-m/p4h) and a control strain SZCgP1 (pEC-XK99E), respectively, and were transformed into an SZCgP2 strain to obtain an overexpression strain SZCgP2 (pEC-mip4h) and a control strain SZCgP2(pEC-XK99E), respectively. The seed culture medium contained the following ingredients (g/L): 5 g/L glucose, 1 g/L yeast powder,

 $3~\mathrm{g/L}$  soybean peptone,  $3~\mathrm{g/L}$  urea,  $0.5~\mathrm{g/L}$  succinic acid, 1g/L K<sub>2</sub>HPO<sub>4</sub>·3H<sub>2</sub>O, 0.1 g/L MgSO<sub>4</sub>·7H<sub>2</sub>O, 0.01 mg/L biotin, 0.1 mg/L vitamin B1, and 20 g/L MOPS. The fermentation culture medium contained the following ingredients: 80 g/L glucose, 1 g/L yeast powder, 1 g/L soybean peptone, 1 g/L NaCl, 1 g/L ammonium sulfate, 6 g/L urea, 1 g/L  $K_2HPO_4\cdot 3H_2O$ , 0.45 g/L  $MgSO_4\cdot 7H_2O$ , 0.2 g/L FeSO<sub>4</sub>·7H<sub>2</sub>O, 0.4 mg/L biotin, 0.1 mg/L vitamin B1, and 40 g/L MOPS, and the initial pH was 7.2. Firstly, the strains were inoculated into a seed culture medium and cultured for 8 h. The cultures were inoculated as seeds into a 24-well plate containing 800 µL of a fermentation culture medium, and the inoculation amount was controlled with the initial  $\mathrm{OD}_{600}$  being 0.1 (as detected by a microplate reader). The seeds were cultured at 30° C. for 18 h, with the rotation speed of a plate shaker being 800 rpm. The experiment for each strain was performed in triplicate.

[0100] After fermentation,  $OD_{600}$  and the yield of trans-4-hydroxy-L-proline and L-proline were detected. The detection of trans-4-hydroxy-L-proline was performed with reference to the China national standard GB/T 9695.23-2008, and the detection of L-proline was performed as described in Example 1. The results are shown in Table 7, indicating that the strains without expression of trans-proline-4-hydroxylase failed to produce trans-4-hydroxy-Lproline, and that the knockout of the L-proline efflux protein thrE gene could remarkably reduce the yield of extracellular L-proline by-products and increase the ratio of trans-4hydroxy-L-proline to L-proline, helping to obtain trans-4hydroxy-L-proline production with higher purity. It is expected that further enhancement of the activity of transproline-4-hydroxylase allows rapid transformation of intracellularly synthesized L-proline to trans-4-hydroxy-L-proline in the strain, and knockout of the L-proline efflux protein thrE gene also reduces the efflux of L-proline to the extracellular space, allowing the yield of trans-4-hydroxy-L-proline to be also increased. Therefore, the knockout of L-proline efflux protein thrE is of great significance to the production of trans-4-hydroxy-L-proline.

mid. The pEC-Ubp4h plasmid and the pEC-XK99E control plasmid were transformed into an SZCgP1 strain to obtain an overexpression strain SZCgP1(pEC-Ubp4h) and a control strain SZCgP1(pEC-XK99E), respectively, and were transformed into an SZCgP2 strain to obtain an overexpression strain SZCgP2(pEC-Ubp4h) and a control strain SZCgP2(pEC-XK99E), respectively. The ingredients in the medium and the culture of the strains were referred to Example 4. The detection of trans-3-hydroxy-L-proline was performed with reference to Patent No. CN110804596A, and the detection of L-proline was performed as described in Example 1. The result shows that the strains without expression of trans-proline-3-hydroxylase failed to produce trans-3-hydroxy-L-proline, and that the knockout of the L-proline efflux protein thrE gene could remarkably reduce the yield of extracellular L-proline by-products and increase the ratio of trans-3-hydroxy-L-proline to L-proline, helping to obtain trans-3-hydroxy-L-proline production with higher purity. That is, the knockout of L-proline efflux protein thrE is of great significance to the production of trans-3-hydroxy-Lproline.

[0102] Hydroxyproline has four natural stereoisomers, namely trans-4-hydroxy-L-proline, cis-4-hydroxy-L-proline, trans-3-hydroxy-L-proline, and cis-3-hydroxy-L-proline, and it is known to those skilled in the art that the four different hydroxyprolines are obtained by directly catalyzing L-proline with corresponding trans-proline-4-hydroxylase, cis-proline-4-hydroxylase, trans-proline-3-hydroxylase, and cis-proline-3-hydroxylase, respectively. Documents in the prior art have also reported that different hydroxyprolines can be produced by overexpressing different proline hydroxylases based on strains producing L-proline (Zhang F, Liu H, Zhang T, Pijning T, Yu L, Zhang W, Liu W, Meng X. Biochemical and genetic characterization of fungal proline hydroxylase in echinocandin biosynthesis. Appl Microbiol Biotechnol. 2018 Sep;102(18):7877-7890. Chen K, Pang Y, Zhang B, Feng J, Xu S, Wang X, Ouyang P. Process optimization for enhancing production of cis-4-hydroxy-Lproline by engineered Escherichia coli. Microb Cell Fact.

TABLE 7

Effect of thrE gene knockout on the yield of extracellular trans-4-hydroxy-L-proline and L-proline										
Strain	OD <sub>600</sub>	Yield of hydroxyproline (g/L)	Yield of proline (g/L)	Ratio of hydroxyproline to proline						
SZCgP1(pEC-XK99E) SZCgP1(pEC-mip4h) SZCgP2(pEC-XK99E) SZCgP2(pEC-mip4h)	16.47 ± 0.94 13.16 ± 0.18 15.52 ± 0.82 14.31 ± 0.22	0.70 ± 0.01 	4.25 ± 0.35 2.94 ± 0.21 1.68 ± 0.08 0.89 ± 0.05	1:4.2 — 1:1.3						

## EXAMPLE 5

# Use of L-Proline Efflux Protein in Production of Hydroxyproline

[0101] To further verify the use of the L-proline efflux protein in the production of other hydroxyproline, in the present disclosure, a plasmid for expressing trans-proline-3-hydroxylase was first constructed, that is, an expression plasmid pEC-Ubp4h for expressing the trans-proline-3-hydroxylase Ubp4h as shown in Patent No. CN110804596A was artificially synthesized based on a pEC-XK99E plas-

2017 Nov. 22;16(1):210. Mori H, Shibasaki T, Yano K, Ozaki A. Purification and cloning of a proline 3-hydroxylase, a novel enzyme which hydroxylates free L-proline to cis-3-hydroxy-L-proline. *J Bacteriol.* 1997 September;179 (18):5677-83). Therefore, for those skilled in the art, in Examples 4 and 5 of the present disclosure, it is demonstrated that the knockout of the L-proline efflux protein ThrE can increase intracellular L-proline concentration, and in the case that, based on this strain, the overexpression of transproline-4-hydroxylase can increase the yield of trans-4-hydroxylase can increase the yield of trans-7-hydroxy-L-proline can increase the yield of trans-7-hydroxy-L-proline.

proline; it is apparent to those skilled in the art that the overexpression of different proline hydroxylases based on the knockout of the L-proline efflux protein ThrE can reduce the yield of extracellular L-proline as by-products and increase the corresponding ratio of hydroxyproline to L-proline, i.e., the knockout of the L-proline efflux protein is of great significance to the production of all of the above 4

hydroxyprolines. The embodiments of the present disclosure have been described above. However, the present disclosure is not limited to the embodiments described above. Any modification, equivalent, improvement, and the like made without departing from the spirit and principle of the present disclosure shall fall within the protection scope of the present disclosure.

### SEQUENCE LISTING

```
<160> NUMBER OF SEQ ID NOS: 23
<210> SEO ID NO 1
<211> LENGTH: 489
<212> TYPE: PRT
<213> ORGANISM: Corynebacterium glutamicum
<400> SEQUENCE: 1
Met Leu Ser Phe Ala Thr Leu Arg Gly Arg Ile Ser Thr Val Asp Ala
Ala Lys Ala Ala Pro Pro Pro Ser Pro Leu Ala Pro Ile Asp Leu Thr
Asp His Ser Gln Val Ala Gly Val Met Asn Leu Ala Ala Arg Ile Gly
Asp Ile Leu Leu Ser Ser Gly Thr Ser Asn Ser Asp Thr Lys Val Gln
Val Arg Ala Val Thr Ser Ala Tyr Gly Leu Tyr Tyr Thr His Val Asp
Ile Thr Leu Asn Thr Ile Thr Ile Phe Thr Asn Ile Gly Val Glu Arg
Lys Met Pro Val Asn Val Phe His Val Val Gly Lys Leu Asp Thr Asn
Phe Ser Lys Leu Ser Glu Val Asp Arg Leu Ile Arg Ser Ile Gln Ala
Gly Ala Thr Pro Pro Glu Val Ala Glu Lys Ile Leu Asp Glu Leu Glu
Gln Ser Pro Ala Ser Tyr Gly Phe Pro Val Ala Leu Leu Gly Trp Ala 145 \, 150 \, 155 \, 160
Met Met Gly Gly Ala Ile Ala Val Leu Leu Gly Gly Gly Trp Gln Val 165 \hspace{1cm} 170 \hspace{1cm} 175 \hspace{1cm}
Ser Leu Ile Ala Phe Ile Thr Ala Phe Thr Ile Ile Ser Thr Thr Ser
                                185
Phe Leu Gly Lys Lys Gly Leu Pro Thr Phe Phe Gln Asn Val Val Gly
                 200
Gly Phe Ile Ala Thr Leu Pro Ala Ser Ile Ala Tyr Ser Leu Ala Leu
                       215
His Phe Gly Leu Glu Ile Lys Pro Ser Gln Ile Ile Ala Ser Gly Ile
                   230
Val Val Leu Leu Ala Gly Leu Thr Leu Val Gln Ser Leu Gln Asp Gly
                         250
Ile Thr Gly Ala Pro Val Thr Ala Ser Ala Arg Phe Phe Glu Thr Leu
Leu Phe Thr Gly Gly Ile Val Ala Gly Val Gly Leu Gly Ile Gln Leu
                            280
Ser Glu Ile Leu His Val Met Leu Pro Ala Met Glu Ser Ala Ala Ala
                      295
```

Ala Ala Ala Phe Ala Val Gly Cys Tyr Ala Glu Trp Ser Ser Val Ile Ile Ala Gly Leu Thr Ala Leu Met Gly Ser Ala Phe Tyr Tyr Leu Phe Val Val Tyr Leu Gly Pro Val Ser Ala Ala Ala Ile Ala Ala Thr Ala Val Gly Phe Thr Gly Gly Leu Leu Ala Arg Arg Phe Leu Ile Pro Pro Leu Ile Val Ala Ile Ala Gly Ile Thr Pro Met Leu Pro Gly Leu Ala Ile Tyr Arg Gly Met Tyr Ala Thr Leu Asn Asp Gln Thr Leu Met Gly 410 Phe Thr Asn Ile Ala Val Ala Leu Ala Thr Ala Ser Ser Leu Ala Ala 425 420 Gly Val Val Leu Gly Glu Trp Ile Ala Arg Arg Leu Arg Arg Pro Pro 440 Arg Phe Asn Pro Tyr Arg Ala Phe Thr Lys Ala Asn Glu Phe Ser Phe Gln Glu Glu Ala Glu Gln Asn Gln Arg Arg Gln Arg Lys Arg Pro Lys 470 475 Thr Asn Gln Arg Phe Gly Asn Lys Arg 485 <210> SEQ ID NO 2 <211> LENGTH: 489 <212> TYPE: PRT <213 > ORGANISM: Corynebacterium glutamicum <400> SEQUENCE: 2 Met Leu Ser Phe Ala Thr Leu Arg Gly Arg Ile Ser Thr Val Asp Ala Ala Lys Ala Ala Pro Pro Pro Ser Pro Leu Ala Pro Ile Asp Leu Thr 25 Asp His Ser Gln Val Ala Gly Val Met Asn Leu Ala Ala Arg Ile Gly Asp Ile Leu Leu Ser Ser Gly Thr Ser Asn Ser Asp Thr Lys Val Gln Val Arg Ala Val Thr Ser Ala Tyr Gly Leu Tyr Tyr Thr His Val Asp Ile Thr Leu Asn Thr Ile Thr Ile Phe Thr Asn Ile Gly Val Glu Arg Lys Met Pro Val Asn Val Phe His Val Val Gly Lys Leu Asp Thr Asn 105 Phe Ser Lys Leu Ser Glu Val Asp Arg Leu Ile Arg Ser Ile Gln Ala 120 Gly Ala Thr Pro Pro Glu Val Ala Glu Lys Ile Leu Asp Glu Leu Glu Gln Ser Pro Ala Ser Tyr Gly Phe Pro Val Ala Leu Leu Gly Trp Ala Met Met Gly Gly Ala Val Ala Val Leu Leu Gly Gly Gly Trp Gln Val

Pro Asn Tyr Ser Ser Thr Phe Ala Arg Ile Ile Ala Gly Gly Val Thr

60

12

Feb. 15, 2024

	-continued														
				165					170					175	
Ser	Leu	Ile	Ala 180	Phe	Ile	Thr	Ala	Phe 185	Thr	Ile	Ile	Ala	Thr 190	Thr	Ser
Phe	Leu	Gly 195	Lys	Lys	Gly	Leu	Pro 200	Thr	Phe	Phe	Gln	Asn 205	Val	Val	Gly
Gly	Phe 210	Ile	Ala	Thr	Leu	Pro 215	Ala	Ser	Ile	Ala	Tyr 220	Ser	Leu	Ala	Leu
Gln 225	Phe	Gly	Leu	Glu	Ile 230	Lys	Pro	Ser	Gln	Ile 235	Ile	Ala	Ser	Gly	Ile 240
Val	Val	Leu	Leu	Ala 245	Gly	Leu	Thr	Leu	Val 250	Gln	Ser	Leu	Gln	Asp 255	Gly
Ile	Thr	Gly	Ala 260	Pro	Val	Thr	Ala	Ser 265	Ala	Arg	Phe	Phe	Glu 270	Thr	Leu
Leu	Phe	Thr 275	Gly	Gly	Ile	Val	Ala 280	Gly	Val	Gly	Leu	Gly 285	Ile	Gln	Leu
Ser	Glu 290	Ile	Leu	His	Val	Met 295	Leu	Pro	Ala	Met	Glu 300	Ser	Ala	Ala	Ala
Pro 305	Asn	Tyr	Ser	Ser	Thr 310	Phe	Ala	Arg	Ile	Ile 315	Ala	Gly	Gly	Val	Thr 320
Ala	Ala	Ala	Phe	Ala 325	Val	Gly	Cys	Tyr	Ala 330	Glu	Trp	Ser	Ser	Val 335	Ile
Ile	Ala	Gly	Leu 340	Thr	Ala	Leu	Met	Gly 345	Ser	Ala	Phe	Tyr	Tyr 350	Leu	Phe
Val	Val	Tyr 355	Leu	Gly	Pro	Val	Ser 360	Ala	Ala	Ala	Ile	Ala 365	Ala	Thr	Ala
Val	Gly 370	Phe	Thr	Gly	Gly	Leu 375	Leu	Ala	Arg	Arg	Phe 380	Leu	Ile	Pro	Pro
Leu 385	Ile	Val	Ala	Ile	Ala 390	Gly	Ile	Thr	Pro	Met 395	Leu	Pro	Gly	Leu	Ala 400
Ile	Tyr	Arg	Gly	Met 405	Tyr	Ala	Thr	Leu	Asn 410	Asp	Gln	Thr	Leu	Met 415	Gly
Phe	Thr	Asn	Ile 420	Ala	Val	Ala	Leu	Ala 425	Thr	Ala	Ser	Ser	Leu 430	Ala	Ala
Gly	Val	Val 435	Leu	Gly	Glu	Trp	Ile 440	Ala	Arg	Arg	Leu	Arg 445	Arg	Pro	Pro
Arg	Phe 450	Asn	Pro	Tyr	Arg	Ala 455	Phe	Thr	Lys	Ala	Asn 460	Glu	Phe	Ser	Phe
Gln 465	Glu	Glu	Ala	Glu	Gln 470	Asn	Gln	Arg	Arg	Gln 475	Arg	Lys	Arg	Pro	Lys 480
Thr	Asn	Gln	Arg	Phe 485	Gly	Asn	ГЛа	Arg							
<210> SEQ ID NO 3 <211> LENGTH: 11773 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: synthesized															
< 400	)> SI	EQUE	ICE :	3											
aattaagett aaaggagttg agaatggata agaaataete aataggetta getateggea									cggca						

caaatagcgt cggatgggcg gtgatcactg atgaatataa ggttccgtct aaaaagttca

aggttctggg	aaatacagac	cgccacagta	tcaaaaaaaa	tcttataggg	gctcttttat	180	
ttgacagtgg	agagacagcg	gaagcgactc	gtctcaaacg	gacagctcgt	agaaggtata	240	
cacgtcggaa	gaatcgtatt	tgttatctac	aggagatttt	ttcaaatgag	atggcgaaag	300	
tagatgatag	tttctttcat	cgacttgaag	agtcttttt	ggtggaagaa	gacaagaagc	360	
atgaacgtca	tcctattttt	ggaaatatag	tagatgaagt	tgcttatcat	gagaaatatc	420	
caactatcta	tcatctgcga	aaaaaattgg	tagattctac	tgataaagcg	gatttgcgct	480	
taatctattt	ggccttagcg	catatgatta	agtttcgtgg	tcattttttg	attgagggag	540	
atttaaatcc	tgataatagt	gatgtggaca	aactatttat	ccagttggta	caaacctaca	600	
atcaattatt	tgaagaaaac	cctattaacg	caagtggagt	agatgctaaa	gcgattcttt	660	
ctgcacgatt	gagtaaatca	agacgattag	aaaatctcat	tgctcagctc	cccggtgaga	720	
agaaaaatgg	cttatttggg	aatctcattg	ctttgtcatt	gggtttgacc	cctaatttta	780	
aatcaaattt	tgatttggca	gaagatgcta	aattacagct	ttcaaaagat	acttacgatg	840	
atgatttaga	taatttattg	gcgcaaattg	gagatcaata	tgctgatttg	tttttggcag	900	
ctaagaattt	atcagatgct	attttacttt	cagatatcct	aagagtaaat	actgaaataa	960	
ctaaggctcc	cctatcagct	tcaatgatta	aacgctacga	tgaacatcat	caagacttga	1020	
ctcttttaaa	agctttagtt	cgacaacaac	ttccagaaaa	gtataaagaa	atcttttttg	1080	
atcaatcaaa	aaacggatat	gcaggttata	ttgatggggg	agctagccaa	gaagaatttt	1140	
ataaatttat	caaaccaatt	ttagaaaaaa	tggatggtac	tgaggaatta	ttggtgaaac	1200	
taaatcgtga	agatttgctg	cgcaagcaac	ggacctttga	caacggctct	attccccatc	1260	
aaattcactt	gggtgagctg	catgctattt	tgagaagaca	agaagacttt	tatccatttt	1320	
taaaagacaa	tcgtgagaag	attgaaaaaa	tcttgacttt	tcgaattcct	tattatgttg	1380	
gtccattggc	gcgtggcaat	agtcgttttg	catggatgac	tcggaagtct	gaagaaacaa	1440	
ttaccccatg	gaattttgaa	gaagttgtcg	ataaaggtgc	ttcagctcaa	tcatttattg	1500	
aacgcatgac	aaactttgat	aaaaatcttc	caaatgaaaa	agtactacca	aaacatagtt	1560	
tgctttatga	gtattttacg	gtttataacg	aattgacaaa	ggtcaaatat	gttactgaag	1620	
gaatgcgaaa	accagcattt	ctttcaggtg	aacagaagaa	agccattgtt	gatttactct	1680	
tcaaaacaaa	tcgaaaagta	accgttaagc	aattaaaaga	agattatttc	aaaaaaatag	1740	
aatgttttga	tagtgttgaa	atttcaggag	ttgaagatag	atttaatgct	tcattaggta	1800	
cctaccatga	tttgctaaaa	attattaaag	ataaagattt	tttggataat	gaagaaaatg	1860	
aagatatctt	agaggatatt	gttttaacat	tgaccttatt	tgaagatagg	gagatgattg	1920	
aggaaagact	taaaacatat	gctcacctct	ttgatgataa	ggtgatgaaa	cagcttaaac	1980	
gtcgccgtta	tactggttgg	ggacgtttgt	ctcgaaaatt	gattaatggt	attagggata	2040	
agcaatctgg	caaaacaata	ttagattttt	tgaaatcaga	tggttttgcc	aatcgcaatt	2100	
ttatgcagct	gatccatgat	gatagtttga	catttaaaga	agacattcaa	aaagcacaag	2160	
tgtctggaca	aggcgatagt	ttacatgaac	atattgcaaa	tttagctggt	agccctgcta	2220	
ttaaaaaagg	tattttacag	actgtaaaag	ttgttgatga	attggtcaaa	gtaatggggc	2280	
	agaaaatatc					2340	
	ttcgcgagag					2400	
Joongaaaaa		- goalgaaac	Jacobyaaya	550000000	Jacouggua	2100	

gtcagattct	taaagagcat	cctgttgaaa	atactcaatt	gcaaaatgaa	aagctctatc	2460
tctattatct	ccaaaatgga	agagacatgt	atgtggacca	agaattagat	attaatcgtt	2520
taagtgatta	tgatgtcgat	gccattgttc	cacaaagttt	ccttaaagac	gattcaatag	2580
acaataaggt	cttaacgcgt	tctgataaaa	atcgtggtaa	atcggataac	gttccaagtg	2640
aagaagtagt	caaaaagatg	aaaaactatt	ggagacaact	tctaaacgcc	aagttaatca	2700
ctcaacgtaa	gtttgataat	ttaacgaaag	ctgaacgtgg	aggtttgagt	gaacttgata	2760
aagctggttt	tatcaaacgc	caattggttg	aaactcgcca	aatcactaag	catgtggcac	2820
aaattttgga	tagtcgcatg	aatactaaat	acgatgaaaa	tgataaactt	attcgagagg	2880
ttaaagtgat	taccttaaaa	tctaaattag	tttctgactt	ccgaaaagat	ttccaattct	2940
ataaagtacg	tgagattaac	aattaccatc	atgcccatga	tgcgtatcta	aatgccgtcg	3000
ttggaactgc	tttgattaag	aaatatccaa	aacttgaatc	ggagtttgtc	tatggtgatt	3060
ataaagttta	tgatgttcgt	aaaatgattg	ctaagtctga	gcaagaaata	ggcaaagcaa	3120
ccgcaaaata	tttcttttac	tctaatatca	tgaacttctt	caaaacagaa	attacacttg	3180
caaatggaga	gattcgcaaa	cgccctctaa	tcgaaactaa	tggggaaact	ggagaaattg	3240
tctgggataa	agggcgagat	tttgccacag	tgcgcaaagt	attgtccatg	ccccaagtca	3300
atattgtcaa	gaaaacagaa	gtacagacag	gcggattctc	caaggagtca	attttaccaa	3360
aaagaaattc	ggacaagctt	attgctcgta	aaaaagactg	ggatccaaaa	aaatatggtg	3420
gttttgatag	tccaacggta	gcttattcag	tcctagtggt	tgctaaggtg	gaaaaaggga	3480
aatcgaagaa	gttaaaatcc	gttaaagagt	tactagggat	cacaattatg	gaaagaagtt	3540
cctttgaaaa	aaatccgatt	gactttttag	aagctaaagg	atataaggaa	gttaaaaaag	3600
acttaatcat	taaactacct	aaatatagtc	tttttgagtt	agaaaacggt	cgtaaacgga	3660
tgctggctag	tgccggagaa	ttacaaaaag	gaaatgagct	ggctctgcca	agcaaatatg	3720
tgaattttt	atatttagct	agtcattatg	aaaagttgaa	gggtagtcca	gaagataacg	3780
aacaaaaaca	attgtttgtg	gagcagcata	agcattattt	agatgagatt	attgagcaaa	3840
tcagtgaatt	ttctaagcgt	gttattttag	cagatgccaa	tttagataaa	gttcttagtg	3900
catataacaa	acatagagac	aaaccaatac	gtgaacaagc	agaaaatatt	attcatttat	3960
ttacgttgac	gaatcttgga	gctcccgctg	cttttaaata	ttttgataca	acaattgatc	4020
gtaaacgata	tacgtctaca	aaagaagttt	tagatgccac	tcttatccat	caatccatca	4080
ctggtcttta	tgaaacacgc	attgatttga	gtcagctagg	aggtgactga	gcttggctgt	4140
tttggcggat	gagagaagat	tttcagcctg	atacagatta	aatcagaacg	cagaagcggt	4200
ctgataaaac	agaatttgcc	tggcggcagt	agcgcggtgg	tcccacctga	ccccatgccg	4260
aactcagaag	tgaaacgccg	tagcgccgat	ggtagtgtgg	ggtctgccca	tgcgagagta	4320
gggaactgcc	aggcatcaaa	taaaacgaaa	ggctcagtcg	aaagactggg	cctttcgttt	4380
tatctgttgt	ttgtcggtga	acgctctcct	gagtaggaca	aatccgccgg	gagcggattt	4440
gaacgttgcg	aagcaacggc	ccggagggtg	gcgggcagga	cgcccgccat	aaactgccag	4500
gcatcaaatt	aagcagaagg	ccatcctgac	ggatggcctt	tttgcgtttc	tacaaactct	4560
tttgtttatt	tttctaaata	cattcaaata	tgtatccgct	catgagacaa	taaccctgat	4620
aaatgcttca	ataatattga	aaaaggaaga	gtatgagtat	tcaacatttc	cgtgtcgccc	4680

ttattccctt	ttttgcggca	ttttgccttc	ctgtttttgc	tcacccagaa	acgctggtga	4740
aagtaaaaga	tgctgaagat	cagttgggtg	cacgagtggg	ttacatcgaa	ctggatctca	4800
acageggtaa	gatccttgag	agttttcgcc	ccgaagaacg	ttttccaatg	atgagcactt	4860
ttgcttcctc	gctcactgac	tegetgeget	cggtcgttcg	gctgcggcga	gcggtatcag	4920
ctcactcaaa	ggcggtaata	cggttatcca	cagaatcagg	ggataacgca	ggaaagaaca	4980
tgtgagcaaa	aggccagcaa	aaggccagga	accgtaaaaa	ggccgcgttg	ctggcgtttt	5040
tccataggct	cegececect	gacgagcatc	acaaaaatcg	acgctcaagt	cagaggtggc	5100
gaaacccgac	aggactataa	agataccagg	cgtttccccc	tggaagctcc	ctcgtgcgct	5160
ctcctgttcc	gaccctgccg	cttaccggat	acctgtccgc	ctttctccct	tcgggaagcg	5220
tggcgctttc	tcaatgctca	cgctgtaggt	atctcagttc	ggtgtaggtc	gttcgctcca	5280
agctgggctg	tgtgcacgaa	cccccgttc	agcccgaccg	ctgcgcctta	tccggtaact	5340
atcgtcttga	gtccaacccg	gtaagacacg	acttatcgcc	actggcagca	gccactggta	5400
acaggattag	cagagcgagg	tatgtaggcg	gtgctacaga	gttcttgaag	tggtggccta	5460
actacggcta	cactagaagg	acagtatttg	gtatctgcgc	tctgctgaag	ccagttacct	5520
tcggaaaaag	agttggtagc	tcttgatccg	gcaaacaaac	caccgctggt	agcggtggtt	5580
tttttgtttg	caagcagcag	attacgcgca	gaaaaaaagg	atctcaagaa	gatcctttga	5640
tcttttctac	ggggtctgac	gctcagtgga	acgaaaactc	acgttaaggg	attttggtca	5700
tgagattatc	aaaaaggatc	ttcacctaga	tccttttggg	gtgggcgaag	aactccagca	5760
tgagatcccc	gcgctggagg	atcatccagc	cattcggggt	cgttcactgg	ttcccctttc	5820
tgatttctgg	catagaagaa	cccccgtgaa	ctgtgtggtt	ccgggggttg	ctgatttttg	5880
cgagacttct	cgcgcaattc	cctagcttag	gtgaaaacac	catgaaacac	tagggaaaca	5940
cccatgaaac	acccattagg	gcagtagggc	ggcttcttcg	tctagggctt	gcatttgggc	6000
ggtgatctgg	tctttagcgt	gtgaaagtgt	gtcgtaggtg	gcgtgctcaa	tgcactcgaa	6060
cgtcacgtca	tttaccgggt	cacggtgggc	aaagagaact	agtgggttag	acattgtttt	6120
cctcgttgtc	ggtggtggtg	agcttttcta	gccgctcggt	aaacgcggcg	atcatgaact	6180
cttggaggtt	ttcaccgttc	tgcatgcctg	cgcgcttcat	gtcctcacgt	agtgccaaag	6240
gaacgcgtgc	ggtgaccacg	acgggcttag	cctttgcctg	cgcttctagt	gcttcgatgg	6300
tggcttgtgc	ctgcgcttgc	tgcgcctgta	gtgcctgttg	agcttcttgt	agttgctgtt	6360
ctagctgtgc	cttggttgcc	atgctttaag	actctagtag	ctttcctgcg	atatgtcatg	6420
cgcatgcgta	gcaaacattg	tcctgcaact	cattcattat	gtgcagtgct	cctgttacta	6480
gtcgtacata	ctcatattta	cctagtctgc	atgcagtgca	tgcacatgca	gtcatgtcgt	6540
gctaatgtgt	aaaacatgta	catgcagatt	gctgggggtg	cagggggcgg	agccaccctg	6600
tccatgcggg	gtgtggggct	tgccccgccg	gtacagacag	tgagcaccgg	ggcacctagt	6660
cgcggatacc	ccccctaggt	atcggacacg	taaccctccc	atgtcgatgc	aaatctttaa	6720
cattgagtac	gggtaagctg	gcacgcatag	ccaagctagg	cggccaccaa	acaccactaa	6780
aaattaatag	tccctagaca	agacaaaccc	ccgtgcgagc	taccaactca	tatgcacggg	6840
ggccacataa	cccgaagggg	tttcaattga	caaccatagc	actagctaag	acaacgggca	6900
caacacccgc	acaaactcgc	actgcgcaac	cccgcacaac	atcgggtcta	ggtaacactg	6960

agtaacactg	aaatagaagt	gaacacctct	aaggaaccgc	aggtcaatga	gggttctaag	7020
gtcactcgcg	ctagggcgtg	gcgtaggcaa	aacgtcatgt	acaagatcac	caatagtaag	7080
gctctggcgg	ggtgccatag	gtggcgcagg	gacgaagctg	ttgcggtgtc	ctggtcgtct	7140
aacggtgctt	cgcagtttga	gggtctgcaa	aactctcact	ctcgctgggg	gtcacctctg	7200
gctgaattgg	aagtcatggg	cgaacgccgc	attgagctgg	ctattgctac	taagaatcac	7260
ttggcggcgg	gtggcgcgct	catgatgttt	gtgggcactg	ttcgacacaa	ccgctcacag	7320
tcatttgcgc	aggttgaagc	gggtattaag	actgcgtact	cttcgatggt	gaaaacatct	7380
cagtggaaga	aagaacgtgc	acggtacggg	gtggagcaca	cctatagtga	ctatgaggtc	7440
acagactctt	gggcgaacgg	ttggcacttg	caccgcaaca	tgctgttgtt	cttggatcgt	7500
ccactgtctg	acgatgaact	caaggcgttt	gaggattcca	tgttttcccg	ctggtctgct	7560
ggtgtggtta	aggccggtat	ggacgcgcca	ctgcgtgagc	acggggtcaa	acttgatcag	7620
gtgtctacct	ggggtggaga	cgctgcgaaa	atggcaacct	acctcgctaa	gggcatgtct	7680
caggaactga	ctggctccgc	tactaaaacc	gcgtctaagg	ggtcgtacac	gccgtttcag	7740
atgttggata	tgttggccga	tcaaagcgac	gccggcgagg	atatggacgc	tgttttggtg	7800
gctcggtggc	gtgagtatga	ggttggttct	aaaaacctgc	gttcgtcctg	gtcacgtggg	7860
gctaagcgtg	ctttgggcat	tgattacata	gacgctgatg	tacgtcgtga	aatggaagaa	7920
gaactgtaca	agctcgccgg	tctggaagca	ccggaacggg	tcgaatcaac	ccgcgttgct	7980
gttgctttgg	tgaagcccga	tgattggaaa	ctgattcagt	ctgatttcgc	ggttaggcag	8040
tacgttctcg	attgcgtgga	taaggctaag	gacgtggccg	ctgcgcaacg	tgtcgctaat	8100
gaggtgctgg	caagtetggg	tgtggattcc	accccgtgca	tgatcgttat	ggatgatgtg	8160
gacttggacg	cggttctgcc	tactcatggg	gacgctacta	agcgtgatct	gaatgcggcg	8220
gtgttcgcgg	gtaatgagca	gactattctt	cgcacccact	aaaagcggca	taaaccccgt	8280
tcgatatttt	gtgcgatgaa	tttatggtca	atgtcgcggg	ggcaaactat	gatgggtctt	8340
gttgttggcg	tcccggaaaa	cgattccgaa	gcccaacctt	tcatagaagg	cggcggtgga	8400
atttttctcc	acataagctg	gcaatgttgc	gacgcaacag	gtacagtgta	attcatgaga	8460
ccacgcgtgg	atccggctta	ctaaaagcca	gataacagta	tgcgtatttg	cgcgctgatt	8520
tttgcggtat	aagaatatat	actgatatgt	atacccgaag	tatgtcaaaa	agaggtatgc	8580
tatgaagcag	cgtattacag	tgacagttga	cagcgacagc	tatcagttgc	tcaaggcata	8640
tatgatgtca	atatctccgg	tctggtaagc	acaaccatgc	agaatgaagc	ccgtcgtctg	8700
cgtgccgaac	gctggaaagc	ggaaaatcag	gaagggatgg	ctgaggtcgc	ccggtttatt	8760
gaaatgaacg	gctcttttgc	tgacgagaac	aggggctggt	gaaatgcagt	ttaaggttta	8820
cacctataaa	agagagagcc	gttatcgtct	gtttgtggat	gtacagagtg	atattattga	8880
cacgcccggg	cgacggatgg	tgatccccct	ggccagtgca	cgtctgctgt	cagataaagt	8940
ctcccgtgaa	ctttacccgg	tggtgcatat	cggggatgaa	agctggcgca	tgatgaccac	9000
cgatatggcc	agtgtgccgg	tatccgttat	cggggaagaa	gtggctgatc	tcagccaccg	9060
cgaaaatgac	atcaaaaacg	ccattaacct	gatgttctgg	ggaatataag	gtctcagttt	9120
tagagctaga	aatagcaagt	taaaataagg	ctagtccgtt	atcaacttga	aaaagtggca	9180
ccgagtcggt	gcttttttc	caggcatcaa	ataaaacgaa	aggctcagtc	gaaagactgg	9240

gccttt	cgtt	ttatctgttg	tttgtcggtg	aacgctctcc	tgagtaggac	aaatccgccg	9300	
ggagc	ggatt	tgaacgttgc	gaagcaacgg	cccggagggt	ggcgggcagg	acgcccgcca	9360	
taaact	gcca	ggcatcaaat	taagcagaag	gccatcctga	cggatggcct	ttttgcgttt	9420	
ctacaa	aactc	tttttgttta	tttttctaaa	tacattcaaa	tatgtatccg	ctcatgaatt	9480	
aattc	cgcta	gatgacgtgc	ggcttcgaaa	atctcgtgat	ggcaggttgg	gcgtcgcttg	9540	
gtcggt	catt	tcgaagggca	ccaataactg	ccttaaaaaa	attacgcccc	gccctgccac	9600	
tcatco	gcagt	actgttgtaa	ttcattaagc	attctgccga	catggaagcc	atcacagacg	9660	
gcatga	atgaa	cctgaatcgc	cagcggcatc	agcaccttgt	cgccttgcgt	ataatatttg	9720	
cccato	ggtga	aaacgggggc	gaagaagttg	tccatattgg	ccacgtttaa	atcaaaactg	9780	
gtgaaa	actca	cccagggatt	ggctgagacg	aaaaacatat	tctcaataaa	ccctttaggg	9840	
aaataq	ggcca	ggttttcacc	gtaacacgcc	acatcttgcg	aatatatgtg	tagaaactgc	9900	
cggaaa	atcgt	cgtggtattc	actccagagc	gatgaaaacg	tttcagtttg	ctcatggaaa	9960	
acggt	gtaac	aagggtgaac	actatcccat	atcaccagct	caccgtcttt	cattgccata	10020	
cggaad	ctccg	gatgagcatt	catcaggcgg	gcaagaatgt	gaataaaggc	cggataaaac	10080	
ttgtg	cttat	ttttctttac	ggtctttaaa	aaggccgtaa	tatccagctg	aacggtctgg	10140	
ttataç	ggtac	attgagcaac	tgactgaaat	gcctcaaaat	gttctttacg	atgccattgg	10200	
gatata	atcaa	cggtggtata	tccagtgatt	tttttctcca	ttttagcttc	cttagctcct	10260	
gaaaat	tctcg	tegaageteg	gcggatttgt	cctactcaag	ctgatccgac	aaaatccaca	10320	
cattat	ccca	ggtgtccgga	tcggtcaaat	acgctgccag	ctcatagacc	gtatccaaag	10380	
catcco	ggggc	tgatccccgg	cgccagggtg	gtttttcttt	tcaccagtga	gacgggcaac	10440	
agctga	attgc	ccttcaccgc	ctggccctga	gagagttgca	gcaagcggtc	cacgtggttt	10500	
gcccca	agcag	gcgaaaatcc	tgtttgatgg	tggttaacgg	cgggatataa	catgagctgt	10560	
cttcg	gtatc	gtcgtatccc	actaccgaga	tatccgcacc	aacgcgcagc	ccggactcgg	10620	
taatg	gegeg	cattgcgccc	agegeeatet	gatcgttggc	aaccagcatc	gcagtgggaa	10680	
cgatgo	ccctc	attcagcatt	tgcatggttt	gttgaaaacc	ggacatggca	ctccagtcgc	10740	
cttcc	egtte	cgctatcggc	tgaatttgat	tgcgagtgag	atatttatgc	cagccagcca	10800	
gacgca	agacg	cgccgagaca	gaacttaatg	ggcccgctaa	cagcgcgatt	tgctggtgac	10860	
ccaato	gcgac	cagatgetee	acgcccagtc	gcgtaccgtc	ttcatgggag	aaaataatac	10920	
tgttga	atggg	tgtctggtca	gagacatcaa	gaaataacgc	cggaacatta	gtgcaggcag	10980	
cttcca	acagc	aatggcatcc	tggtcatcca	gcggatagtt	aatgatcagc	ccactgacgc	11040	
gttgc	gcgag	aagattgtgc	accgccgctt	tacaggette	gacgccgctt	cgttctacca	11100	
tegaca	accac	cacgctggca	cccagttgat	cggcgcgaga	tttaatcgcc	gcgacaattt	11160	
gcgac	ggcgc	gtgcagggcc	agactggagg	tggcaacgcc	aatcagcaac	gactgtttgc	11220	
cegeea	agttg	ttgtgccacg	cggttgggaa	tgtaattcag	ctccgccatc	gccgcttcca	11280	
ctttt	cccg	cgttttcgca	gaaacgtggc	tggcctggtt	caccacgcgg	gaaacggtct	11340	
gataaq	gagac	accggcatac	tctgcgacat	cgtataacgt	tactggtttc	acattcacca	11400	
ccctga	aattg	actctcttcc	gggcgctatc	atgccatacc	gcgaaaggtt	ttgcaccatt	11460	
cgatg	gtgtc	aacgtaaatg	ccgcttcgcc	ttcgcgcgcg	aattgcaagc	tgatccgggc	11520	
3.		J	-		=			

-continued	
ttatcgactg cacggtgcac caatgcttct ggcgtcaggc agccatcgga agctgtggta	11580
tggctgtgca ggtcgtaaat cactgcataa ttcgtgtcgc tcaaggcgca ctcccgttct	11640
ggataatgtt ttttgcgccg acatcataac ggttctggca aatattctga aatgagctgt	11700
tgacaattaa tcatcggctc gtataatgtg tggaattgtg agcggataac aatttcacac	11760
aggaaacaga att	11773
<210> SEQ ID NO 4 <211> LENGTH: 11773 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: synthesized	
<400> SEQUENCE: 4	
aattaagett aaaggeacce gatatggata agaaatacte aataggetta gatateggea	60
caaatagcgt cggatgggcg gtgatcactg atgaatataa ggttccgtct aaaaagttca	120
aggttctggg aaatacagac cgccacagta tcaaaaaaaa tcttataggg gctcttttat	180
ttgacagtgg agagacagcg gaagcgactc gtctcaaacg gacagctcgt agaaggtata	240
cacgtcggaa gaatcgtatt tgttatctac aggagatttt ttcaaatgag atggcgaaag	300
tagatgatag tttctttcat cgacttgaag agtctttttt ggtggaagaa gacaagaagc	360
atgaacgtca tcctattttt ggaaatatag tagatgaagt tgcttatcat gagaaatatc	420
caactatcta tcatctgcga aaaaaattgg tagattctac tgataaagcg gatttgcgct	480
taatctattt ggccttagcg catatgatta agtttcgtgg tcattttttg attgagggag	540
atttaaatcc tgataatagt gatgtggaca aactatttat ccagttggta caaacctaca	600
atcaattatt tgaagaaaac cctattaacg caagtggagt agatgctaaa gcgattcttt	660
ctgcacgatt gagtaaatca agacgattag aaaatctcat tgctcagctc cccggtgaga	720
agaaaaatgg cttatttggg aatctcattg ctttgtcatt gggtttgacc cctaatttta	780
aatcaaattt tgatttggca gaagatgcta aattacagct ttcaaaagat acttacgatg	840
atgatttaga taatttattg gcgcaaattg gagatcaata tgctgatttg tttttggcag	900
ctaagaattt atcagatgct attttacttt cagatatcct aagagtaaat actgaaataa	960
ctaaggctcc cctatcagct tcaatgatta aacgctacga tgaacatcat caagacttga	1020
ctcttttaaa agctttagtt cgacaacaac ttccagaaaa gtataaagaa atctttttg	1080
atcaatcaaa aaacggatat gcaggttata ttgatggggg agctagccaa gaagaatttt	1140
ataaatttat caaaccaatt ttagaaaaaa tggatggtac tgaggaatta ttggtgaaac	1200
taaatcgtga agatttgctg cgcaagcaac ggacctttga caacggctct attccccatc	1260
aaattcactt gggtgagctg catgctattt tgagaagaca agaagacttt tatccatttt	1320
taaaagacaa togtgagaag attgaaaaaa tottgacttt togaattoot tattatgttg	1380
gtccattggc gcgtggcaat agtcgttttg catggatgac tcggaagtct gaagaaacaa	1440
ttaccccatg gaattttgaa gaagttgtcg ataaaggtgc ttcagctcaa tcatttattg	1500
aacgcatgac aaactttgat aaaaatcttc caaatgaaaa agtactacca aaacatagtt	1560
tgctttatga gtattttacg gtttataacg aattgacaaa ggtcaaatat gttactgaag	1620
J J J and Jacobana Journal Journal Journal	

gaatgcgaaa accagcattt ctttcaggtg aacagaagaa agccattgtt gatttactct 1680

tcaaaacaaa	tcgaaaagta	accgttaagc	aattaaaaga	agattatttc	aaaaaaatag	1740
aatgttttga	tagtgttgaa	atttcaggag	ttgaagatag	atttaatgct	tcattaggta	1800
cctaccatga	tttgctaaaa	attattaaag	ataaagattt	tttggataat	gaagaaaatg	1860
aagatatctt	agaggatatt	gttttaacat	tgaccttatt	tgaagatagg	gagatgattg	1920
aggaaagact	taaaacatat	gctcacctct	ttgatgataa	ggtgatgaaa	cagcttaaac	1980
gtcgccgtta	tactggttgg	ggacgtttgt	ctcgaaaatt	gattaatggt	attagggata	2040
agcaatctgg	caaaacaata	ttagattttt	tgaaatcaga	tggttttgcc	aatcgcaatt	2100
ttatgcagct	gatccatgat	gatagtttga	catttaaaga	agacattcaa	aaagcacaag	2160
tgtctggaca	aggcgatagt	ttacatgaac	atattgcaaa	tttagctggt	agccctgcta	2220
ttaaaaaagg	tattttacag	actgtaaaag	ttgttgatga	attggtcaaa	gtaatggggc	2280
ggcataagcc	agaaaatatc	gttattgaaa	tggcacgtga	aaatcagaca	actcaaaagg	2340
gccagaaaaa	ttcgcgagag	cgtatgaaac	gaatcgaaga	aggtatcaaa	gaattaggaa	2400
gtcagattct	taaagagcat	cctgttgaaa	atactcaatt	gcaaaatgaa	aagctctatc	2460
tctattatct	ccaaaatgga	agagacatgt	atgtggacca	agaattagat	attaatcgtt	2520
taagtgatta	tgatgtcgat	cacattgttc	cacaaagttt	ccttaaagac	gattcaatag	2580
acaataaggt	cttaacgcgt	tctgataaaa	atcgtggtaa	atcggataac	gttccaagtg	2640
aagaagtagt	caaaaagatg	aaaaactatt	ggagacaact	tctaaacgcc	aagttaatca	2700
ctcaacgtaa	gtttgataat	ttaacgaaag	ctgaacgtgg	aggtttgagt	gaacttgata	2760
aagctggttt	tatcaaacgc	caattggttg	aaactcgcca	aatcactaag	catgtggcac	2820
aaattttgga	tagtcgcatg	aatactaaat	acgatgaaaa	tgataaactt	attcgagagg	2880
ttaaagtgat	taccttaaaa	tctaaattag	tttctgactt	ccgaaaagat	ttccaattct	2940
ataaagtacg	tgagattaac	aattaccatc	atgcccatga	tgcgtatcta	aatgccgtcg	3000
ttggaactgc	tttgattaag	aaatatccaa	aacttgaatc	ggagtttgtc	tatggtgatt	3060
ataaagttta	tgatgttcgt	aaaatgattg	ctaagtctga	gcaagaaata	ggcaaagcaa	3120
ccgcaaaata	tttcttttac	tctaatatca	tgaacttctt	caaaacagaa	attacacttg	3180
caaatggaga	gattcgcaaa	cgccctctaa	tcgaaactaa	tggggaaact	ggagaaattg	3240
tctgggataa	agggcgagat	tttgccacag	tgcgcaaagt	attgtccatg	ccccaagtca	3300
atattgtcaa	gaaaacagaa	gtacagacag	gcggattctc	caaggagtca	attttaccaa	3360
aaagaaattc	ggacaagctt	attgctcgta	aaaaagactg	ggatccaaaa	aaatatggtg	3420
gttttgatag	tccaacggta	gcttattcag	tcctagtggt	tgctaaggtg	gaaaaaggga	3480
aatcgaagaa	gttaaaatcc	gttaaagagt	tactagggat	cacaattatg	gaaagaagtt	3540
cctttgaaaa	aaatccgatt	gactttttag	aagctaaagg	atataaggaa	gttaaaaaag	3600
acttaatcat	taaactacct	aaatatagtc	tttttgagtt	agaaaacggt	cgtaaacgga	3660
tgctggctag	tgccggagaa	ttacaaaaag	gaaatgagct	ggctctgcca	agcaaatatg	3720
tgaattttt	atatttagct	agtcattatg	aaaagttgaa	gggtagtcca	gaagataacg	3780
aacaaaaaca	attgtttgtg	gagcagcata	agcattattt	agatgagatt	attgagcaaa	3840
tcagtgaatt	ttctaagcgt	gttattttag	cagatgccaa	tttagataaa	gttcttagtg	3900
catataacaa	acatagagac	aaaccaatac	gtgaacaagc	agaaaatatt	attcatttat	3960

ttacgttgac	gaatcttgga	gctcccgctg	cttttaaata	ttttgataca	acaattgatc	4020
gtaaacgata	tacgtctaca	aaagaagttt	tagatgccac	tcttatccat	caatccatca	4080
ctggtcttta	tgaaacacgc	attgatttga	gtcagctagg	aggtgactga	agettggetg	4140
ttttggcgga	tgagagaaga	ttttcagcct	gatacagatt	aaatcagaac	gcagaagcgg	4200
tctgataaaa	cagaatttgc	ctggcggcag	tagcgcggtg	gtcccacctg	accccatgcc	4260
gaactcagaa	gtgaaacgcc	gtagegeega	tggtagtgtg	gggtctgccc	atgcgagagt	4320
agggaactgc	caggcatcaa	ataaaacgaa	aggeteagte	gaaagactgg	gcctttcgtt	4380
ttatctgttg	tttgtcggtg	aacgctctcc	tgagtaggac	aaatccgccg	ggagcggatt	4440
tgaacgttgc	gaagcaacgg	cccggagggt	ggcgggcagg	acgcccgcca	taaactgcca	4500
ggcatcaaat	taagcagaag	gccatcctga	cggatggcct	ttttgcgttt	ctacaaactc	4560
ttttgtttat	ttttctaaat	acattcaaat	atgtatccgc	tcatgagaca	ataaccctga	4620
taaatgcttc	aataatattg	aaaaaggaag	agtatgagta	ttcaacattt	ccgtgtcgcc	4680
cttattccct	tttttgcggc	attttgcctt	cctgtttttg	ctcacccaga	aacgctggtg	4740
aaagtaaaag	atgctgaaga	tcagttgggt	gcacgagtgg	gttacatcga	actggatctc	4800
aacagcggta	agatccttga	gagttttcgc	cccgaagaac	gttttccaat	gatgagcact	4860
tttgcttcct	cgctcactga	ctcgctgcgc	tcggtcgttc	ggctgcggcg	agcggtatca	4920
gctcactcaa	aggcggtaat	acggttatcc	acagaatcag	gggataacgc	aggaaagaac	4980
atgtgagcaa	aaggccagca	aaaggccagg	aaccgtaaaa	aggccgcgtt	gctggcgttt	5040
ttccataggc	teegeeeee	tgacgagcat	cacaaaaatc	gacgctcaag	tcagaggtgg	5100
cgaaacccga	caggactata	aagataccag	gcgtttcccc	ctggaagctc	cctcgtgcgc	5160
tctcctgttc	cgaccctgcc	gcttaccgga	tacctgtccg	cctttctccc	ttcgggaagc	5220
gtggcgcttt	ctcaatgctc	acgctgtagg	tatctcagtt	cggtgtaggt	cgttcgctcc	5280
aagctgggct	gtgtgcacga	accccccgtt	cagcccgacc	gctgcgcctt	atccggtaac	5340
tatcgtcttg	agtccaaccc	ggtaagacac	gacttatcgc	cactggcagc	agccactggt	5400
aacaggatta	gcagagcgag	gtatgtaggc	ggtgctacag	agttcttgaa	gtggtggcct	5460
aactacggct	acactagaag	gacagtattt	ggtatctgcg	ctctgctgaa	gccagttacc	5520
ttcggaaaaa	gagttggtag	ctcttgatcc	ggcaaacaaa	ccaccgctgg	tagcggtggt	5580
ttttttgttt	gcaagcagca	gattacgcgc	agaaaaaaag	gatctcaaga	agatcctttg	5640
atcttttcta	cggggtctga	cgctcagtgg	aacgaaaact	cacgttaagg	gattttggtc	5700
atgagattat	caaaaaggat	cttcacctag	atccttttgg	ggtgggcgaa	gaactccagc	5760
atgagatccc	cgcgctggag	gatcatccag	ccattcgggg	tcgttcactg	gttccccttt	5820
ctgatttctg	gcatagaaga	acccccgtga	actgtgtggt	teegggggtt	gctgattttt	5880
gcgagacttc	tcgcgcaatt	ccctagctta	ggtgaaaaca	ccatgaaaca	ctagggaaac	5940
acccatgaaa	cacccattag	ggcagtaggg	cggcttcttc	gtctagggct	tgcatttggg	6000
cggtgatctg	gtctttagcg	tgtgaaagtg	tgtcgtaggt	ggcgtgctca	atgcactcga	6060
acgtcacgtc	atttaccggg	tcacggtggg	caaagagaac	tagtgggtta	gacattgttt	6120
tcctcgttgt	cggtggtggt	gagcttttct	agccgctcgg	taaacgcggc	gatcatgaac	6180
tcttggaggt	tttcaccgtt	ctgcatgcct	gcgcgcttca	tgtcctcacg	tagtgccaaa	6240

ggaacgcgtg	cggtgaccac	gacgggctta	gcctttgcct	gegettetag	tgcttcgatg	6300
gtggcttgtg	cctgcgcttg	ctgcgcctgt	agtgcctgtt	gagettettg	tagttgctgt	6360
tctagctgtg	ccttggttgc	catgctttaa	gactctagta	gctttcctgc	gatatgtcat	6420
gcgcatgcgt	agcaaacatt	gtcctgcaac	tcattcatta	tgtgcagtgc	tcctgttact	6480
agtcgtacat	actcatattt	acctagtctg	catgcagtgc	atgcacatgc	agtcatgtcg	6540
tgctaatgtg	taaaacatgt	acatgcagat	tgctgggggt	gcagggggcg	gagccaccct	6600
gtccatgcgg	ggtgtggggc	ttgccccgcc	ggtacagaca	gtgagcaccg	gggcacctag	6660
tegeggatae	ccccctagg	tatcggacac	gtaaccctcc	catgtcgatg	caaatcttta	6720
acattgagta	cgggtaagct	ggcacgcata	gccaagctag	gcggccacca	aacaccacta	6780
aaaattaata	gtccctagac	aagacaaacc	cccgtgcgag	ctaccaactc	atatgcacgg	6840
gggccacata	acccgaaggg	gtttcaattg	acaaccatag	cactagctaa	gacaacgggc	6900
acaacacccg	cacaaactcg	cactgcgcaa	ccccgcacaa	catcgggtct	aggtaacact	6960
gagtaacact	gaaatagaag	tgaacacctc	taaggaaccg	caggtcaatg	agggttctaa	7020
ggtcactcgc	gctagggcgt	ggcgtaggca	aaacgtcatg	tacaagatca	ccaatagtaa	7080
ggctctggcg	gggtgccata	ggtggcgcag	ggacgaagct	gttgcggtgt	cctggtcgtc	7140
taacggtgct	tcgcagtttg	agggtctgca	aaactctcac	tctcgctggg	ggtcatctct	7200
ggctgaattg	gaagtcatgg	gcgaacgccg	cattgagctg	gctattgcta	ctaagaatca	7260
cttggcggcg	ggtggcgcgc	tcatgatgtt	tgtgggcact	gttcgacaca	accgctcaca	7320
gtcatttgcg	caggttgaag	cgggtattaa	gactgcgtac	tcttcgatgg	tgaaaacatc	7380
tcagtggaag	aaagaacgtg	cacggtacgg	ggtggagcac	acctatagtg	actatgaggt	7440
cacagactct	tgggcgaacg	gttggcactt	gcaccgcaac	atgctgttgt	tcttggatcg	7500
tccactgtct	gacgatgaac	tcaaggcgtt	tgaggattcc	atgttttccc	gctggtctgc	7560
tggtgtggtt	aaggccggta	tggacgcgcc	actgcgtgag	cacggggtca	aacttgatca	7620
ggtgtctacc	tggggtggag	acgctgcgaa	aatggcaacc	tacctcgcta	agggcatgtc	7680
tcaggaactg	actggctccg	ctactaaaac	cgcgtctaag	gggtcgtaca	cgccgtttca	7740
gatgttggat	atgttggccg	atcaaagcga	cgccggcgag	gatatggacg	ctgttttggt	7800
ggctcggtgg	cgtgagtatg	aggttggttc	taaaaacctg	cgttcgtcct	ggtcacgtgg	7860
ggctaagcgt	gctttgggca	ttgattacat	agacgctgat	gtacgtcgtg	aaatggaaga	7920
agaactgtac	aagctcgccg	gtctggaagc	accggaacgg	gtcgaatcaa	cccgcgttgc	7980
tgttgctttg	gtgaagcccg	atgattggaa	actgattcag	tctgatttcg	cggttaggca	8040
gtacgttctc	gattgcgtgg	ataaggctaa	ggacgtggcc	gctgcgcaac	gtgtcgctaa	8100
tgaggtgctg	gcaagtctgg	gtgtggattc	caccccgtgc	atgatcgtta	tggatgatgt	8160
ggacttggac	gcggttctgc	ctactcatgg	ggacgctact	aagcgtgatc	tgaatgegge	8220
ggtgttcgcg	ggtaatgagc	agactattct	tegeacecae	taaaagcggc	ataaaccccg	8280
ttcgatattt	tgtgcgatga	atttatggtc	aatgtcgcgg	gggcaaacta	tgatgggtct	8340
tgttgttggc	gtcccggaaa	acgattccga	agcccaacct	ttcatagaag	gcggcggtgg	8400
aatttttctc	cacataagct	ggcaatgttg	cgacgcaaca	ggtacagtgt	aattcatgag	8460
	gateeggett					8520
3 3 3		5	5 5-	5 5		

ttttgcggta	taagaatata	tactgatatg	tatacccgaa	gtatgtcaaa	aagaggtatg	8580	
ctatgaagca	gcgtattaca	gtgacagttg	acagcgacag	ctatcagttg	ctcaaggcat	8640	
atatgatgtc	aatatctccg	gtctggtaag	cacaaccatg	cagaatgaag	cccgtcgtct	8700	
gcgtgccgaa	cgctggaaag	cggaaaatca	ggaagggatg	gctgaggtcg	cccggtttat	8760	
tgaaatgaac	ggctcttttg	ctgacgagaa	caggggctgg	tgaaatgcag	tttaaggttt	8820	
acacctataa	aagagagagc	cgttatcgtc	tgtttgtgga	tgtacagagt	gatattattg	8880	
acacgcccgg	gcgacggatg	gtgatccccc	tggccagtgc	acgtctgctg	tcagataaag	8940	
tctcccgtga	actttacccg	gtggtgcata	teggggatga	aagctggcgc	atgatgacca	9000	
ccgatatggc	cagtgtgccg	gtatccgtta	tcggggaaga	agtggctgat	ctcagccacc	9060	
gcgaaaatga	catcaaaaac	gccattaacc	tgatgttctg	gggaatataa	ggtctcagtt	9120	
ttagagctag	aaatagcaag	ttaaaataag	gctagtccgt	tatcaacttg	aaaaagtggc	9180	
accgagtcgg	tgctttttt	ccaggcatca	aataaaacga	aaggctcagt	cgaaagactg	9240	
ggcctttcgt	tttatctgtt	gtttgtcggt	gaacgctctc	ctgagtagga	caaatccgcc	9300	
gggagcggat	ttgaacgttg	cgaagcaacg	gcccggaggg	tggcgggcag	gacgcccgcc	9360	
ataaactgcc	aggcatcaaa	ttaagcagaa	ggccatcctg	acggatggcc	tttttgcgtt	9420	
tctacaaact	ctttttgttt	atttttctaa	atacattcaa	atatgtatcc	gctcatgaat	9480	
taattccgct	agatgacgtg	cggcttcgaa	aatctcgtga	tggcaggttg	ggcgtcgctt	9540	
ggtcggtcat	ttcgaagggc	accaataact	gccttaaaaa	aattacgccc	cgccctgcca	9600	
ctcatcgcag	tactgttgta	attcattaag	cattctgccg	acatggaagc	catcacagac	9660	
ggcatgatga	acctgaatcg	ccagcggcat	cagcaccttg	tcgccttgcg	tataatattt	9720	
gcccatggtg	aaaacggggg	cgaagaagtt	gtccatattg	gccacgttta	aatcaaaact	9780	
ggtgaaactc	acccagggat	tggctgagac	gaaaaacata	ttctcaataa	accctttagg	9840	
gaaataggcc	aggttttcac	cgtaacacgc	cacatcttgc	gaatatatgt	gtagaaactg	9900	
ccggaaatcg	tcgtggtatt	cactccagag	cgatgaaaac	gtttcagttt	gctcatggaa	9960	
aacggtgtaa	caagggtgaa	cactatccca	tatcaccagc	tcaccgtctt	tcattgccat	10020	
acggaactcc	ggatgagcat	tcatcaggcg	ggcaagaatg	tgaataaagg	ccggataaaa	10080	
cttgtgctta	tttttcttta	cggtctttaa	aaaggccgta	atatccagct	gaacggtctg	10140	
gttataggta	cattgagcaa	ctgactgaaa	tgcctcaaaa	tgttctttac	gatgccattg	10200	
ggatatatca	acggtggtat	atccagtgat	ttttttctcc	attttagctt	ccttagctcc	10260	
tgaaaatctc	gtcgaagctc	ggcggatttg	tcctactcaa	gctgatccga	caaaatccac	10320	
acattatccc	aggtgtccgg	atcggtcaaa	tacgctgcca	gctcatagac	cgtatccaaa	10380	
gcatccgggg	ctgatccccg	gcgccagggt	ggttttctt	ttcaccagtg	agacgggcaa	10440	
cagctgattg	cccttcaccg	cctggccctg	agagagttgc	agcaagcggt	ccacgtggtt	10500	
tgccccagca	ggcgaaaatc	ctgtttgatg	gtggttaacg	gcgggatata	acatgagctg	10560	
tcttcggtat	cgtcgtatcc	cactaccgag	atatccgcac	caacgcgcag	cccggactcg	10620	
		cagcgccatc				10680	
		ttgcatggtt				10740	
		ctgaatttga				10800	
concogni	ceyclalegg	cigaattiga	ceyeyayeya	gacacctatg	ccagccagcc	10000	

agacgcagac gcgccgagac agaacttaat gggcccgcta acagcgcgat ttgctggtga	10860
cccaatgcga ccagatgctc cacgcccagt cgcgtaccgt cttcatggga gaaaataata	10920
ctgttgatgg gtgtctggtc agagacatca agaaataacg ccggaacatt agtgcaggca	10980
gettecacag caatggeate etggteatee ageggatagt taatgateag eccaetgaeg	11040
cgttgcgcga gaagattgtg caccgccgct ttacaggctt cgacgccgct tcgttctacc	11100
atcgacacca ccacgctggc acccagttga tcggcgcgag atttaatcgc cgcgacaatt	11160
tgcgacggcg cgtgcagggc cagactggag gtggcaacgc caatcagcaa cgactgtttg	11220
cccgccagtt gttgtgccac gcggttggga atgtaattca gctccgccat cgccgcttcc	11280
actttttccc gcgttttcgc agaaacgtgg ctggcctggt tcaccacgcg ggaaacggtc	11340
tgataagaga caccggcata ctctgcgaca tcgtataacg ttactggttt cacattcacc	11400
accetgaatt gactetette egggegetat eatgecatae egegaaaggt tttgeaccat	11460
togatggtgt caacgtaaat googottogo ottogogogo gaattgcaag otgatoogg	11520
cttatcgact gcacggtgca ccaatgcttc tggcgtcagg cagccatcgg aagctgtggt	11580
atggctgtgc aggtcgtaaa tcactgcata attcgtgtcg ctcaaggcgc actcccgttc	11640
tggataatgt tttttgcgcc gacatcataa cggttctggc aaatattctg aaatgagctg	11700
ttgacaatta atcatcggct cgtataatgt gtggaattgt gagcgctcac aatttcacac	11760
aggaaacaga att	11773
<pre>&lt;210&gt; SEQ ID NO 5 &lt;211&gt; LENGTH: 807 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: synthesized</pre>	
<211> LENGTH: 807 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:	
<211> LENGTH: 807 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: synthesized	60
<211> LENGTH: 807 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: synthesized <400> SEQUENCE: 5	60 120
<pre>&lt;211&gt; LENGTH: 807 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: synthesized &lt;400&gt; SEQUENCE: 5 atgttgtcgt acgagagtat cgacctgtat cgcgaggacg ggttcctgtt cgcggacccc</pre>	
<pre>&lt;211&gt; LENGTH: 807 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: synthesized &lt;400&gt; SEQUENCE: 5 atgttgtcgt acgagagtat cgacctgtat cgcgaggacg ggttcctgtt cgcggacccc cttaccgaaa aggagacaga ccttctacgc gaacaggccg atcgtgagtt tctgcgggat</pre>	120
<pre>&lt;211&gt; LENGTH: 807 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: synthesized &lt;400&gt; SEQUENCE: 5 atgttgtcgt acgagagtat cgacctgtat cgcgaggacg ggttcctgtt cgcggacccc cttaccgaaa aggagacaga ccttctacgc gaacaggccg atcgtgagtt tctgcgggat tctcccggcc ggatgttgga gaaggacgt ttcacggtgc gcgggtgca cgggtcgcac</pre>	120 180
<pre>&lt;211&gt; LENGTH: 807 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: synthesized &lt;400&gt; SEQUENCE: 5 atgttgtcgt acgagagtat cgacctgtat cgcgaggacg ggttcctgtt cgcggacccc cttaccgaaa aggagacaga ccttctacgc gaacaggccg atcgtgagtt tctgcgggat tctcccggcc ggatgttgga gaaggacgt ttcacggtgc gcggggtgca cgggtcgcac gtggtgaaca gcacgttcgc ccggctggta cggcacccaa agatcgtcac accggccacg</pre>	120 180 240
<pre>&lt;211&gt; LENGTH: 807 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: synthesized &lt;400&gt; SEQUENCE: 5  atgttgtcgt acgagagtat cgacctgtat cgcgaggacg ggttcctgtt cgcggacccc cttaccgaaa aggagacaga ccttctacgc gaacaggccg atcgtgagtt tctgcgggat tctcccggcc ggatgttgga gaaggacggt ttcacggtgc gcgggtgca cgggtcgcac gtggtgaaca gcacgttcgc ccggctggta cggcacccaa agatcgtcac accggccacg cagctactgg gtggccccgt atatgtgcac cagttcaaga tcaatgcaaa gaaggcgctg</pre>	120 180 240 300
<pre>&lt;211&gt; LENGTH: 807 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: synthesized &lt;400&gt; SEQUENCE: 5 atgttgtcgt acgagagtat cgacctgtat cgcgaggacg ggttcctgtt cgcggacccc cttaccgaaa aggagacaga ccttctacgc gaacaggccg atcgtgagtt tctgcgggat tctcccggcc ggatgttgga gaaggacggt ttcacggtgc gcggggtgca cgggtcgcac gtggtgaaca gcacgttcgc ccggctggta cggcacccaa agatcgtcac accggccacg cagctactgg gtggccccgt atatgtgcac cagttcaaga tcaatgcaaa gaaggcgctg accggcgatg tgtggccctg gcaccaggac tacatcttct ggaaccgggg tgacggaatg</pre>	120 180 240 300 360
<pre>&lt;211&gt; LENGTH: 807 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: synthesized &lt;400&gt; SEQUENCE: 5  atgttgtcgt acgagagtat cgacctgtat cgcgaggacg ggttcctgtt cgcggacccc cttaccgaaa aggagacaga ccttctacgc gaacaggccg atcgtgagtt tctgcgggat tctcccggcc ggatgttgga gaaggacggt ttcacggtgc gcggggtgca cgggtcgcac gtggtgaaca gcacgttcgc ccggctggta cggcaccaa agatcgtcac accggccacg cagctactgg gtggccccgt atatgtgcac cagttcaaga tcaatgcaaa gaaggcgctg accggcgatg tgtggccctg gcaccaggac tacatcttct ggaaccgggg tgacggaatg cgtcgccccg acgtggtgaa cgtcgccgtc ctgctggatg aggcgaccga tctgaacggt</pre>	120 180 240 300 360 420
<pre>&lt;211&gt; LENGTH: 807 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: synthesized &lt;400&gt; SEQUENCE: 5  atgttgtcgt acgagagtat cgacctgtat cgcgaggacg ggttcctgtt cgcggacccc cttaccgaaa aggagacaga ccttctacgc gaacaggccg atcgtgagtt tctgcgggat tctcccggcc ggatgttgga gaaggacggt ttcacggtgc gcggggtgca cgggtcgcac gtggtgaaca gcacgttcgc ccggctggta cggcaccaa agatcgtcac accggccacg cagctactgg gtggccccgt atatgtgcac cagttcaaga tcaatgcaaa gaaggcgctg accggcgatg tgtggccctg gcaccaggac tacatcttct ggaaccgggg tgacggaatg cgtcgccccg acgtggtgaa cgtcgccgtc ctgctggatg aggcgaccga tctgaacggt ccactgctcg tcctgcccgg ctcacacaag tgcggctctc tggaagtggc gaggcggacg</pre>	120 180 240 300 360 420
<pre>&lt;211&gt; LENGTH: 807 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: synthesized &lt;400&gt; SEQUENCE: 5  atgttgtcgt acgagagtat cgacctgtat cgcgaggacg ggttcctgtt cgcggacccc cttaccgaaa aggagacaga ccttctacgc gaacaggccg atcgtgagtt tctgcgggat tctcccggcc ggatgttgga gaaggacggt ttcacggtge gcggggtgca cgggtcgcac gtggtgaaca gcacgttcgc ccggctggta cggcacccaa agatcgtcac accggccacg cagctactgg gtggccccgt atatgtgcac cagttcaaga tcaatgcaaa gaaggcgctg accggcgatg tgtggccctg gcaccaggac tacatcttct ggaaccgggg tgacggaatg cgtcgccccg acgtggtgaa cgtcgccgtc ctgctggatg aggcgaccga tctgaacggt ccactgctcg tcctgcccgg ctcacacaag tgcggctctc tggaagtggc gaggcggacg accgtctgtg gcgacgggc gtggcggtcc gacatctccg cagatctgga ctacgccatc</pre>	120 180 240 300 360 420 480
<pre>&lt;211&gt; LENGTH: 807 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: synthesized &lt;400&gt; SEQUENCE: 5  atgttgtcgt acgagagtat cgacctgtat cgcgaggacg ggttcctgtt cgcggacccc cttaccgaaa aggagacaga ccttctacgc gaacaggccg atcgtgagtt tctgcgggat tctcccggcc ggatgttgga gaaggacggt ttcacggtgc gcggggtgca cgggtcgcac gtggtgaaca gcacgttcgc ccggctggta cggcacccaa agatcgtcac accggccacg cagctactgg gtggccccgt atatgtgcac cagttcaaga tcaatgcaaa gaaggcgctg accggcgatg tgtggccctg gcaccaggac tacatcttct ggaaccgggg tgacggaatg cgtcgcccc acgtggtgaa cgtcgccgtc ctgctggatg aggcgaccga tctgaacggt ccactgctcg tcctgcccgg ctcacacaag tgcggctctc tggaagtggc gaggcggacg accgtctgtg gcgacgggc gtggcggtcc gacatctccg cagatctgga ctacgccatc gacgccccc tgctgtccaa gctcaccgag actacaaaag tgaccgccat caaagggccg</pre>	120 180 240 300 360 420 480 540 600
<pre>&lt;211&gt; LENGTH: 807 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: synthesized &lt;400&gt; SEQUENCE: 5  atgttgtcgt acgagagtat cgacctgtat cgcgaggacg ggttcctgtt cgcggacccc cttaccgaaa aggagacaga ccttctacgc gaacaggccg atcgtgagtt tctgcgggat tctcccggcc ggatgttgga gaaggacggt ttcacggtgc gcggggtgca cgggtcgcac gtggtgaaca gcacgttcgc ccggctggta cggacccaa agatcgtcac accggccacg cagctactgg gtggccccgt atatgtgcac cagttcaaga tcaatgcaaa gaaggcgctg accggcgatg tgtggccctg gcaccaggac tacatcttct ggaaccgggg tgacggaatg cgtcgccccg acgtggtgaa cgtcgccgtc ctgctggatg aggcgaccga tctgaacggt ccactgctcg tcctgcccgg ctcacacaag tgcggctctc tggaagtggc gaggcggacg accgtctgtg gcgaccgggc gtggcggtcc gacatctccg cagatctgga ctacgccatc gacgccccc tgctgtccaa gctcaccgag actacaaaag tgaccgccat caaagggccg cccggctcga tcctcctctt cgatccctg ctcgtacacg cctcgggcgt gaacatggct</pre>	120 180 240 300 360 420 480 540 600 660

807

gaccccggcg cggaccttct cgcctaa

<sup>&</sup>lt;210> SEQ ID NO 6 <211> LENGTH: 24 <212> TYPE: DNA

```
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223 > OTHER INFORMATION: synthesized
<400> SEQUENCE: 6
ttcacactgc tcgaacttgt acct
                                                                        24
<210> SEQ ID NO 7
<211> LENGTH: 24
<212> TYPE: DNA
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223 > OTHER INFORMATION: synthesized
<400> SEQUENCE: 7
aaacaggtac aagttcgagc agtg
                                                                        24
<210> SEQ ID NO 8
<211> LENGTH: 78
<212> TYPE: DNA
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthesized
<400> SEQUENCE: 8
gcgctcacaa tttcacacag gaaacagaat taattaagct taaaggcacc cgatatggat
                                                                        60
                                                                        78
aagaaatact caataggc
<210> SEQ ID NO 9
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthesized
<400> SEQUENCE: 9
tcagtcacct cctagctgac tcaaatc
                                                                        27
<210> SEQ ID NO 10
<211> LENGTH: 42
<212> TYPE: DNA
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthesized
<400> SEQUENCE: 10
                                                                        42
gtcagctagg aggtgactga agcttggctg ttttggcgga tg
<210> SEQ ID NO 11
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223 > OTHER INFORMATION: synthesized
<400> SEQUENCE: 11
ctgtgtgaaa ttgtgagcgc tcacaattcc
                                                                        30
<210> SEQ ID NO 12
<211> LENGTH: 21
<212> TYPE: DNA
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
```

-continued	
<223> OTHER INFORMATION: synthesized	
<400> SEQUENCE: 12	
tcgaagggca ccaataactg c	21
<210> SEQ ID NO 13 <211> LENGTH: 24 <212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: synthesized	
<400> SEQUENCE: 13	
cttttacttt caccagcgtt tctg	24
<210> SEQ ID NO 14 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: synthesized	
<400> SEQUENCE: 14	
aacgctggtg aaagtaaaag atgc	24
<210> SEQ ID NO 15 <211> LENGTH: 45 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: synthesized	
<400> SEQUENCE: 15	
gaatggaacg gatcaaacgg tgaattacac tgtacctgtt gcgtc	45
<210> SEQ ID NO 16 <211> LENGTH: 43 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: synthesized	
<400> SEQUENCE: 16	
ccgtttgatc cgttccattc gttttagagc tagaaatagc aag	43
<210> SEQ ID NO 17 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: synthesized	
<400> SEQUENCE: 17	
caacctgcca tcacgagatt ttc	23
<210> SEQ ID NO 18 <211> LENGTH: 40 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: synthesized	
<400> SEQUENCE: 18	

aatctcgtga tggcaggttg acgggagcct aagtgaaatg	40
aaccogega oggonggoog aogggagood angegaaacg	••
<210> SEQ ID NO 19	
<211> LENGTH: 41	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: synthesized	
<400> SEQUENCE: 19	
ccttggtaaa tgcacggtat gggtcagtga gatcaatcgg g	41
<210> SEQ ID NO 20	
<211> LENGTH: 22	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: synthesized	
400 GEOVERNATION OF	
<400> SEQUENCE: 20	
ccataccgtg catttaccaa gg	22
<210> SEQ ID NO 21	
<211> LENGTH: 40	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: synthesized	
<400> SEQUENCE: 21	
	40
cagttattgg tgcccttcga ctttgtggtc ttctttgcgg	40
-210, CEO ID NO 22	
<210> SEQ ID NO 22 <211> LENGTH: 39	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: synthesized	
400. CEOUDIGE 00	
<400> SEQUENCE: 22	
	20
acaggccaaa ggagttgaga atgttgagtt ttgcgaccc	39
<210> SEQ ID NO 23	
<211> LENGTH: 40	
<212> TYPE: DNA	
<213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: synthesized	
<400> SEQUENCE: 23	
ccaagettge atgeetgeag ttacetttta ttacegaate	40

- 1. Use of a polypeptide in producing L-proline or hydroxyproline, wherein the polypeptide is:
  - A) a polypeptide having an amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2; or
  - B) a polypeptide having some amino acids added or deleted at either or both ends of the polypeptide of A) but still having the activity of an L-proline efflux function; or
  - C) a polypeptide having higher than 90%, 95%, 96%, 97%, 98%, or 99% homology to the polypeptide of A) and derived from Corynebacterium with the activity of an L-proline efflux function;
  - preferably, the polypeptide has an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2.
- **2.** A strain for producing L-proline, wherein the strain expresses the following polypeptide:
  - A) a polypeptide having an amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2; or
  - B) a polypeptide having some amino acids added or deleted at either or both ends of the polypeptide of A) but still having the activity of an L-proline efflux function; or
  - C) a polypeptide having higher than 90%, 95%, 96%, 97%, 98%, or 99% homology to the polypeptide of A) and derived from Corynebacterium with the activity of an L-proline efflux function;
  - preferably, the polypeptide has an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2;
  - preferably, the strain is a bacterium;
  - preferably, the strain is selected from Escherichia and Corynebacterium, preferably Escherichia coli and Corynebacterium glutamicum, more preferably Corynebacterium glutamicum, and more particularly Corynebacterium glutamicum ATCC 13032, Corynebacterium glutamicum ATCC 13869, Corynebacterium glutamicum B253, and Corynebacterium glutamicum ATCC 14067;
  - more preferably, glutamate kinase in the bacterium is not subjected to feedback inhibition by L-proline or is attenuated feedback inhibition by L-proline;
  - even more preferably, the activity of glutamate kinase and/or glutamate-semialdehyde dehydrogenase and/or pyrroline-5-carboxylate reductase in the bacterium is enhanced
- 3. A method for producing L-proline, wherein the method comprises: culturing the strain of claim 2 to produce L-proline:
  - preferably, the method further comprises a step of isolating L-proline from a fermentation broth.
- **4.** A method for constructing the strain for producing L-proline of claim **2**, wherein the method comprises enhancing the activity of the following polypeptide in the strain:
  - A) a polypeptide having an amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2; or
  - B) a polypeptide having some amino acids added or deleted at either or both ends of the polypeptide of A) but still having the activity of an L-proline efflux function; or
  - C) a polypeptide having higher than 90%, 95%, 96%, 97%, 98%, or 99% homology to the polypeptide of A) and derived from Corynebacterium with the activity of an L-proline efflux function;

- preferably, the polypeptide has an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2;
- preferably, the strain is a bacterium;
- preferably, the strain is selected from Escherichia and Corynebacterium, preferably Escherichia coli and Corynebacterium glutamicum, more preferably Corynebacterium glutamicum, and more particularly Corynebacterium glutamicum ATCC 13032, Corynebacterium glutamicum ATCC13869, Corynebacterium glutamicum B253, and Corynebacterium glutamicum ATCC 14067;
- more preferably, glutamate kinase in the bacterium is not subjected to feedback inhibition by L-proline or is subjected to an attenuated feedback inhibition by L-proline;
- even more preferably, the activity of glutamate kinase and/or glutamate-semialdehyde dehydrogenase and/or pyrroline-5-carboxylate reductase in the bacterium is enhanced.
- **5**. A host cell for producing hydroxyproline, wherein the activity of a polypeptide having an L-proline efflux function in the host cell is attenuated, wherein the polypeptide having the activity of the L-proline efflux function is:
  - A) a polypeptide having an amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2; or
  - B) a polypeptide having some amino acids added or deleted at either or both ends of the polypeptide of A) but still having the activity of the L-proline efflux function; or
  - C) a polypeptide having higher than 90%, 95%, 96%, 97%, 98%, or 99% homology to the polypeptide of A) and derived from Corynebacterium with the activity of an L-proline efflux function;
  - preferably, the host cell is selected from Escherichia and Corynebacterium, preferably Escherichia coli and Corynebacterium glutamicum, more preferably Corynebacterium glutamicum, and more particularly Corynebacterium glutamicum ATCC 13032, Corynebacterium glutamicum ATCC13869, Corynebacterium glutamicum B253, and Corynebacterium glutamicum ATCC 14067;
  - more preferably, glutamate kinase in the host cell is not subjected to feedback inhibition by L-proline or is subjected to an attenuated feedback inhibition by L-proline;
  - even more preferably, the activity of a proline hydroxylase in the host cell is enhanced;
  - even more preferably, the activity of glutamate kinase and/or glutamate-semialdehyde dehydrogenase and/or pyrroline-5-carboxylate reductase in the host cell is enhanced.
- **6**. The host cell as claimed in claim **5**, wherein the proline hydroxylase is trans-proline-4-hydroxylase having a nucleotide sequence as set forth in SEQ ID NO: 5.
- 7. A method for producing hydroxyproline, wherein the method comprises: culturing the host cell of claim 5 to produce hydroxyproline;
  - preferably, the method further comprises a step of isolating hydroxyproline from a fermentation broth.
- **8**. A method for constructing the host cell for producing hydroxyproline of claim **5**, wherein the method comprises:

- (1) attenuating the activity of a polypeptide having an L-proline efflux function in the cell, wherein the polypeptide having the activity of the L-proline efflux function is:
- A) a polypeptide having an amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2 and having the activity of the L-proline efflux function; or
- B) a polypeptide having some amino acids added or deleted at either or both ends of the polypeptide of A) but still having the activity of the L-proline efflux function; or
- C) a polypeptide having higher than 90%, 95%, 96%, 97%, 98%, or 99% homology to the polypeptide of A) and derived from Corynebacterium with the activity of an L-proline efflux function;
- (2) relieving or attenuating feedback inhibition by L-proline on glutamate kinase; and
- (3) introducing a gene encoding a proline hydroxylase into the cell obtained in step (2);
- preferably, the activity of glutamate kinase and/or glutamate-semialdehyde dehydrogenase and/or pyrroline-5-carboxylate reductase in the host cell is enhanced.
- **9**. The method for constructing the host cell for producing hydroxyproline as claimed in claim **8**, wherein the proline hydroxylase is trans-proline-4-hydroxylase having a nucleotide sequence as set forth in SEQ ID NO: 5.

\* \* \* \* \*